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DISCLAIMER 
Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic 
Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human 
Services. 
This information is distributed solely for the purpose of pre dissemination public comment under 
applicable information quality guidelines.  It has not been formally disseminated by the Agency for Toxic 
Substances and Disease Registry.  It does not represent and should not be construed to represent any 
agency determination or policy. 
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FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a relevance to public health discussion which would allow a public health professional to 
make a real-time determination of whether the presence of a particular substance in the environment 
poses a potential threat to human health.  The adequacy of information to determine a substance's health 
effects is described in a health effects summary.  Data needs that are of significance to the protection of 
public health are identified by ATSDR and EPA. 
Each profile includes the following: 
(A) The examination, summary, and interpretation of available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human
exposure for the substance and the associated acute, intermediate, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is
available or in the process of development to determine the levels of exposure that present a
significant risk to human health due to acute, intermediate, and chronic duration exposures;
and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  ATSDR plans 
to revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use. 
Electronic comments may be submitted via: www.regulations.gov.  Follow the on-line instructions for 
submitting comments. 
Written comments may also be sent to:  Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences 
Environmental Toxicology Branch 
Regular Mailing Address: Physical Mailing Address: 
1600 Clifton Road, N.E. 4770 Buford Highway 
Mail Stop S102-1 Building 102, 1st floor, MS S102-1 
Atlanta, Georgia 30329-4027 Chamblee, Georgia 30341 
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The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that 
pose the most significant potential threat to human health, as determined by ATSDR and the EPA.  
Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a 
toxicological profile for each substance on the list.  In addition, ATSDR has the authority to prepare 
toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and 
maintain inventory of literature, research, and studies on the health effects of toxic substances” under 
CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as 
otherwise necessary to support the site-specific response actions conducted by ATSDR.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review.  Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR. 
Patrick N. Breysse, Ph.D., CIH 
Director, National Center for Environmental Health and 
Agency for Toxic Substances and Disease Registry 
Centers for Disease Control and Prevention 
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CHAPTER 1.  RELEVANCE TO PUBLIC HEALTH 
1.1   OVERVIEW AND U.S. EXPOSURES 
ATSDR’s Toxicological Profile for Chlorobenzene was released in 1990.  In order to update the literature 
in this profile, ATSDR conducted a literature search focused on health effects information as described in 
Appendix B.  Chapters 2 and 3 were revised to reflect the most current health effects data.  In some cases, 
other sections of the profile were updated as needed or for consistency with the updated health effects 
data.  However, the focus of the update to this profile is on health effects information. 
Chlorobenzene (C6H5Cl; CAS Number 108-90-7) is used as a solvent and as an intermediate in industry, a 
portion of which is lost to the environment in water and air discharges.  Chlorobenzene adsorbs 
moderately to soil and is biodegraded comparatively rapidly. 
The most likely sources of potential exposure of the general population to chlorobenzene are from 
breathing air, drinking water, or eating food contaminated with chlorobenzene.  However, chlorobenzene 
has been detected in only very small quantities in air, water, and limited food sources.  In a study of urban 
volatile organic compound (VOC) concentrations in the United States between 1996 and 1997, the 
highest levels of chlorobenzene were <1 ppbv (<4.6 µg/m3) at 13 monitoring stations (Mahmoud et al. 
2002).  The potential for toxic exposure to chlorobenzene via the water supply may be somewhat limited 
by the relatively low solubility of chlorobenzene in water, as evidenced by the fact that environmental 
levels of chlorobenzene in groundwater and surface water are generally in the low ppb range (e.g., Van 
Wijk et al. 2004; Zogorski et al. 2006). 
According to the results of the Centers for Disease Control and Prevention (CDC) Fourth National Health 
and Nutrition Examination Survey (NHANES IV), blood levels in the general public were undetectable at 
a limit of detection (LOD) of 0.011 ng/mL, also expressed as 0.011 ppb or 11 parts per trillion (ppt) 
(CDC 2018). 
1.2   SUMMARY OF HEALTH EFFECTS 
• Available data, mostly from animal studies, identify the liver, kidney, and nervous system as
principal targets of chlorobenzene, as illustrated in Figures 1-1 and 1-2 for inhalation and oral
exposure, respectively.
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Figure 1-1.  Health Effects Found in Animals Following Inhalation Exposure to 
Chlorobenzene 
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Figure 1-2.  Health Effects Found in Animals Following Oral Exposure to 
Chlorobenzene 
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• Results from oral studies in rats and mice indicate that the immunological system may be a target
of chlorobenzene toxicity; however, tests of immune function in chlorobenzene-treated animals
have not been performed.
• Results from limited animal studies suggest possible chlorobenzene-induced hematological
effects.
• It is not clear whether chlorobenzene may cause cancer in humans.
Hematological Effects.  Limited animal data suggest that chlorobenzene may exert adverse effects on red 
blood cell parameters (Dilley 1977) and cause leukopenia and lymphocytosis (Zub 1978).  Decreases in 
hematocrit, hemoglobin, and/or red blood cell (RBC) counts and changes in white blood cell (WBC) 
counts were noted in dogs administered chlorobenzene orally for 13 weeks (Monsanto Co. 1967b). 
Hepatic Effects.  Available information regarding the potential for chlorobenzene-induced hepatic effects 
in humans is limited to a single case report of severe liver necrosis in a suicidal male alcoholic (Babany et 
al. 1991; Reygagne et al. 1992).  The liver was identified as a target of chlorobenzene toxicity in 
laboratory animals following inhalation or oral exposure; effects included increased liver weight and 
histopathologic liver lesions (e.g., hepatocellular hypertrophy, vacuolation, degeneration/necrosis) 
(Monsanto Co. 1967a, 1967b; Nair et al. 1987; NTP 1985). 
Renal Effects.  The kidney was identified as a target of chlorobenzene toxicity in laboratory animals 
following inhalation or oral exposure; effects included increased kidney weight and histopathologic 
kidney lesions (e.g., tubular dilatation, interstitial nephritis, degeneration/focal necrosis of proximal 
tubules, foci of regenerative epithelium) (Monsanto Co. 1967b; Nair et al. 1987; NTP 1985). 
Immunological Effects.  Results from 13-week studies of orally-exposed rats and mice suggest that 
chlorobenzene may affect the immune system; effects observed included myeloid and/or lymphoid 
depletion in bone marrow, spleen, and/or thymus (NTP 1985).  However, no data were located regarding 
testing of immune function in animals exposed to chlorobenzene. 
Neurological Effects.  Case reports of humans demonstrated that chlorobenzene caused disturbances of 
the central nervous system, but there were no reports of changes in the structure of the brain or other parts 
of the nervous system.  Neurological effects (e.g., headaches, dizziness, sleepiness) were observed in 
humans who inhaled vapors of chlorobenzene in the workplace for up to 2 years (Rozenbaum et al. 1947).  
CHLOROBENZENE  5 
 
1.  RELEVANCE TO PUBLIC HEALTH 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
However, quantitative exposure data were not available.  Acute inhalation data from animals confirm the 
neurotoxicity of chlorobenzene at high exposure concentrations (Rozenbaum et al. 1947). 
 
Cancer.  No studies were found regarding the carcinogenicity of chlorobenzene in humans.  In a chronic 
bioassay in animals, chlorobenzene (up to 120 mg/kg/day) did not produce increased tumor incidences in 
mice of either sex or in female rats (NTP 1985).  High-dose (120 mg/kg/day) male rats exhibited 
statistically significantly increased incidence of neoplastic liver nodules.  Based on available information 
from animal carcinogenicity studies and genotoxicity evaluations, the U.S. Environmental Protection 
Agency (EPA) (IRIS 2003) assigned chlorobenzene to group D (not classifiable as to human 
carcinogenicity). 
 
1.3   MINIMAL RISK LEVELS (MRLs) 
 
As presented in Figure 1-3, available data have identified the liver and kidney as sensitive targets of 
chlorobenzene toxicity following inhalation exposure.  No inhalation MRLs were derived for 
chlorobenzene due to insufficient data (see Appendix A).  As presented in Figure 1-4, available data have 
identified the liver and kidney as sensitive targets of chlorobenzene toxicity following oral exposure.  The 
oral database was considered adequate for derivation of an intermediate-duration oral MRL for 
chlorobenzene.  The MRL value is summarized in Table 1-1 and discussed in detail in Appendix A.  The 
database was not considered adequate for derivation of acute- or chronic-duration oral MRLs (see 
Appendix A). 
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Figure 1-3.  Summary of Sensitive Targets of Chlorobenzene – Inhalation 
  
The liver and kidney are the most sensitive targets of chlorobenzene inhalation exposure.   
Numbers in circles are the lowest LOAELs for all health effects in animals; no human data were identified. 
 
 
 
 
Figure 1-4.  Summary of Sensitive Targets of Chlorobenzene – Oral 
  
The liver is the most sensitive target of chlorobenzene oral exposure.   
Numbers in circles are the lowest LOAELs for all health effects in animals. 
No reliable dose response data were available for humans. 
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Table 1-1.  Minimal Risk Levels (MRLs) for Chlorobenzenea 
Exposure 
duration MRL Critical effect 
Point of 
departure 
Uncertainty 
factor Reference 
Inhalation exposure (ppm) 
Acute Insufficient data for MRL derivation 
Intermediate Insufficient data for MRL derivation 
Chronic Insufficient data for MRL derivation 
Oral exposure (mg/kg/day) 
Acute Insufficient data for MRL derivation 
Intermediate 28 (NOAEL) 100 Monsanto Co. 
1967b 
Chronic 
0.07 (provisional) Liver lesions 
Insufficient data for MRL derivation 
aSee Appendix A for additional information. 
NOAEL = no-observed-adverse-effect level 
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CHAPTER 2.  HEALTH EFFECTS 
2.1   INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of chlorobenzene.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.  
When available, mechanisms of action are discussed along with the health effects data; toxicokinetic 
mechanistic data are discussed in Section 3.1.   
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
To help public health professionals and others address the needs of persons living or working near hazardous 
waste sites, the information in this section is organized by health effect.  These data are discussed in terms of 
route of exposure (inhalation, oral, and dermal) and three exposure periods:  acute (≤14 days), intermediate 
(15–364 days), and chronic (≥365 days). 
As discussed in Appendix B, a literature search was conducted to identify relevant studies examining health 
effect endpoints.  Figure 2-1 provides an overview of the database of studies in humans or experimental 
animals included in this chapter of the profile.  These studies evaluate the potential health effects associated 
with inhalation, oral, or dermal exposure to chlorobenzene, but may not be inclusive of the entire body of 
literature.   
Animal inhalation studies are presented in Table 2-1 and Figure 2-2, and animal oral studies are presented 
in Table 2-2 and Figure 2-3; no dose-response dermal data were identified for chlorobenzene.   
Levels of significant exposure (LSEs) for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an endpoint should be 
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classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these endpoints.  ATSDR believes 
that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less 
serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  Levels of exposure to chlorobenzene associated with cancer (Cancer Effect 
Levels, CELs) are indicated in Table 2-2 and Figure 2-3.   
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for LSEs and MRLs. 
Human data regarding the potential health effects of chlorobenzene exposure are essentially limited to 
reports of clinical signs of neurotoxicity among occupationally-exposed workers and among volunteers 
exposed by inhalation. 
As illustrated in Figure 2-1, available animal data suggest the following sensitive targets of chlorobenzene 
toxicity: 
• Hepatic endpoint:  Inhalation or oral exposure of animals to chlorobenzene resulted in hepatic
effects such as liver weight increases and dose-related increased incidence and severity of
histopathologic liver effects such as hepatocellular hypertrophy and degenerative and
regenerative liver lesions.
• Renal endpoint:  Inhalation or oral exposure of animals to chlorobenzene resulted in renal
effects such as increased kidney weight and dose-related increased incidence and severity of
histopathologic kidney effects such as tubular dilatation, interstitial nephritis, and degenerative
and regenerative kidney lesions.
• Neurotoxicity endpoint:  Occupational and voluntary inhalation exposure to chlorobenzene has
been associated with clinical signs of neurotoxicity such as numbness, cyanosis, muscle spasms,
drowsiness, headache, ocular pain, and sore throat.  Neurotoxic signs in animals exposed to
chlorobenzene by inhalation or gavage include ataxia, decreased activity, salivation, prostration,
and narcosis.
• Immunological endpoint:  Lymphoid depletion/necrosis in thymus and/or spleen, and myeloid
depletion in bone marrow were reported among rats and/or mice in 13-week gavage studies.
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Figure 2-1.  Overview of the Number of Studies Examining Chlorobenzene Health Effects 
Most studies examined the potential body weight, hepatic, and renal effects of chlorobenzene 
The majority of the studies examined inhalation or oral exposure in animals; limited data were identified for humans (counts represent the 
number of studies examining endpoint) 
*Includes studies discussed in Chapter 2.  A total of 22 studies (including those finding no effect) have examined toxicity; most studies examined multiple
endpoints.
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Table 2-1.  Levels of Significant Exposure to Chlorobenzene – Inhalation 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
ACUTE EXPOSURE 
1 Rat 
(Sprague-
Dawley) 
5 M, 5 F 
30 minutes 2,990, 
5,850, 
7,970 
BW, CS, GN, 
HP, LE, OW 
Bd Wt 7,970 
Hepatic 7,970 
Renal 7,970 
Ocular 2,990 Squinting, lacrimation 
Neuro 2,990 5,850 Ataxia, narcosis 
Shell Oil Co. 1991 
2 Mouse 2 hours LE Death 4,300 100% mortality 
Rozenbaum et al. 1947 
3 Rabbit 2 hours LE Death 537 
Rozenbaum et al. 1947 
4 Rat (Fischer 
344) 
32–33 F 
GDs 6–15 
6 hours/day 
0, 75, 
210, 590 
BW, DX, FI, 
FX, LE, MX, 
OW, TG, WI 
Bd Wt 590 
Develop 590 
John et al. 1984 
5 Rabbit (New 
Zealand 
white) 
30 F 
GDs 6–18 
6 hours/day 
0, 75, 
210, 590 
BW, DX, FI, 
FX, LE, MX, 
OW, TG, WI 
Bd Wt 590 
Develop 590 
John et al. 1984 
6 Rabbit (New 
Zealand 
white) 
30 F 
GDs 6–18 
6 hours/day 
0, 10, 30, 
75, 590 
BW, DX, FI, 
FX, LE, MX, 
OW, TG, WI 
Bd Wt 590 
Develop 590 
John et al. 1984 
7 Guinea pig 
(Hartley 
albino) 
5 M, 5 F 
30 minutes 2,990, 
5,850, 
7,970 
BW, CS, GN, 
HP, LE, OW 
Bd Wt 7,970 
Hepatic 7,970 
Renal 7,970 
Ocular 2,990 Squinting, lacrimation 
Neuro 2,990 5,850 Salivation, narcosis 
Shell Oil Co. 1991 
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Table 2-1.  Levels of Significant Exposure to Chlorobenzene – Inhalation 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
INTERMEDIATE EXPOSURE 
8 Rat 
(Sprague-
Dawley) 
30 M, 30 F 
2 generations 
18–20 weeks 
per generation 
6 hours/day 
9, 50, 
150, 450  
BW, CS, FI, 
DX, GN, HP, 
LE, OF, OW 
Bd Wt 450    
Hepatic 50 M 
450 F 
150 M  Increased mean relative liver weight, 
increased incidence of hepatocellular 
hypertrophy in parental males 
Renal 50 M 
450 F 
150 M  Renal lesions including chronic 
interstitial nephritis and foci of 
regenerative epithelium in parental 
males 
Repro 150 M 
450 F 
450 M  Increased incidence of degeneration of 
testicular germinal epithelium in the 
absence of apparent effects on fertility 
Develop 450    
Nair et al. 1987 (data also reported in Chem Manuf Assoc 1986) 
9 Rat 
(Sprague-
Dawley) 
32 M 
Up to 
24 weeks 
5 days/week 
7 hours/day 
0, 75, 250 BC, BW, CS, 
EA, FI, GN, 
HE, HP, LE, 
OF, OW 
Bd Wt 250    
Hemato 250    
Hepatic 250    
Dilley 1977 
10 Mouse 
(Swiss) 
5 M, 5 F 
3 weeks 
7 hours/day 
0, 543 BW, CS, HE, 
LE 
Death   543 5/10 mice died 
Zub 1978 
11 Rabbit 
(NS) 
32 M 
Up to 
24 weeks 
5 days/week 
7 hours/day 
0, 75, 250 BC, BW, CS, 
EA, FI, GN, 
HE, HP, LE, 
OF, OW 
Bd Wt 250    
Hemato 250    
Hepatic 250    
Dilley 1977 
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Table 2-1.  Levels of Significant Exposure to Chlorobenzene – Inhalation 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(ppm) 
Parameters 
monitored Endpoint 
NOAEL 
(ppm) 
Less 
serious 
LOAEL 
(ppm) 
Serious 
LOAEL 
(ppm) Effect 
12 Dog 
(beagle) 
6 M, 6 F 
6 months 
5 days/week 
6 hours/day 
0, 173.8, 
349.8, 
453.2 
BC, BW, CS, 
EA, FI, GN, 
HE, HP, LE, 
OF, UR 
Bd Wt 453.2 
Hemato 453.2 
Hepatic 453.2 
Renal 453.2 
Monsanto Co. 1980 
aThe number corresponds to entries in Figure 2-2; differences in levels of health effects and cancer effects between male and females are not indicated in 
Figure 2-2.  Where such differences exist, only the levels of effect for the most sensitive gender are presented. 
BC = serum (blood) chemistry; Bd Wt or BW = body weight; CS = clinical signs; EA = enzyme activity; Develop = developmental; DX = developmental toxicity; 
F = female(s); FI = food intake; FX = fetal toxicity; GD = gestation day(s); GN = gross necropsy; HE = hematology; Hemato = hematological; HP = histopathology; 
LE = lethality; LOAEL = lowest-observed-adverse-effect level; M = male(s); MX = maternal toxicity; Neuro = neurological; NOAEL = no-observed-adverse-effect 
level; NS = not specified; OF = organ function; OW = organ weight; Repro = reproductive; TG = teratogenicity; UR = urinalysis; WI = water intake 
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Figure 2-2.  Levels of Significant Exposure to Chlorobenzene – Inhalation 
Acute (≤14 days) 
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Figure 2-2.  Levels of Significant Exposure to Chlorobenzene – Inhalation
Intermediate (15-364 days) 
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Table 2-2.  Levels of Significant Exposure to Chlorobenzene – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
ACUTE EXPOSURE 
1 Rat 
(F344/N) 
5 M, 5 F 
Once 
(GO) 
250, 500, 
1,000, 2,000, 
4,000 
CS, LE Death   4,000 3/5 males and 4/5 females 
died 
Neuro 2,000  4,000 Prostration 
NTP 1985 (data also reported in Kluwe et al. 1985) 
2 Rat (albino) 
22 F 
GDs 6–15 
1 time/day 
(GO) 
0, 100, 300 BW, CS, DX, 
FX, LE, MX, 
TG 
Bd Wt 300    
Develop 300    
Monsanto Co. 1977 
3 Rat 
(F344/N) 
5 M, 5 F 
14 days 
1 time/day 
(GO) 
0, 125, 250, 
500, 1,000, 
2,000 
BW, CS, GN, 
LE 
Death   1,000 5/5 males and 5/5 females 
died 
Bd Wt 500    
Neuro 500  1,000 Prostration 
NTP 1985 (data also reported in Kluwe et al. 1985) 
4 Mouse 
(B6C3F1) 
5 M, 5 F 
Once 
(GO) 
250, 500, 
1,000, 2,000, 
4,000 
CS, LE Death   1,000 M 
2,000 F 
5/5 males died 
5/5 females died 
NTP 1985 (data also reported in Kluwe et al. 1985) 
5 Mouse 
(B6C3F1) 
5 M, 5 F 
14 days 
1 time/day 
(GO) 
0, 30, 60, 125, 
250, 500 
BW, CS, GN, 
LE 
Bd Wt 500    
NTP 1985 (data also reported in Kluwe et al. 1985) 
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Table 2-2.  Levels of Significant Exposure to Chlorobenzene – Oral 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
INTERMEDIATE EXPOSURE 
6 Rat 
(F344/N) 
10 M, 10 F 
13 weeks 
5 days/week 
1 time/day 
(GO) 
0, 60, 125, 
250, 500, 750 
BC, BW, CS, 
GN, HE, HP, 
LE, OW, UR 
Death 500 4/10 males and 3/10 females 
died 
Bd Wt 125 M 
250 F 
250 M 
500 F 
12% lower mean final body 
weight 
Hepatic 125 M 
60 F 
250 M 
125 F 
750 M, F Males: 24% increased mean 
relative liver weight at 
250 mg/kg/day; hepatic 
degeneration/necrosis at 
750 mg/kg/day 
Females: 19% increased 
mean relative liver weight at 
125 mg/kg/day; hepatic 
degeneration/necrosis at 
750 mg/kg/day 
Renal 250 500 750 F 13–15% increased mean 
relative kidney weight at 
500 mg/kg/day; renal 
necrosis/degeneration in 
females at 750 mg/kg/day 
Immuno 500 750 Myeloid depletion in bone 
marrow, lymphoid depletion in 
spleen 
NTP 1985 (data also reported in Kluwe et al. 1985) 
7 Rat 
(albino) 
18 M, 18 F 
3 months 
1 time/day 
(GO) 
Controls 
(untreated), 
12.5, 50, 100, 
250 
BC, BW, CS, 
FI, GN, HE, 
HP, LE, OF, 
OW, UR 
Bd Wt 250 
Hemato 250 
Hepatic 100 250 27–29% increased liver weight 
Renal 100 250 13–14% increased kidney 
weight 
Monsanto Co. 1967a 
CHLOROBENZENE  18 
 
2.  HEALTH EFFECTS 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 2-2.  Levels of Significant Exposure to Chlorobenzene – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
8 Mouse 
(B6C3F1) 
10 M, 10 F 
13 weeks 
5 days/week 
1 time/day 
(GO) 
0, 60, 125, 
250, 500, 750 
BC, BW, CS, 
GN, HE, HP, 
LE, OW, UR 
Death   250 5/9 males and 4/10 females 
died 
Bd Wt 125 M 
250 F 
250 M 
500 F 
 15–20% lower mean final body 
weight at lethal dose levels 
Hepatic 60 M 
125 F 
125 M 250 M, F At 125 mg/kg/day: 14% 
increased mean relative liver 
weight in males 
At 250 mg/kg/day: 29–35% 
increased mean relative liver 
weight and hepatic 
necrosis/degeneration 
Renal 125  250 Renal necrosis/degeneration 
Immuno 125  250 Males: lymphoid 
depletion/necrosis in thymus 
and spleen; myeloid depletion 
in bone marrow 
Females: lymphoid 
depletion/necrosis in spleen 
NTP 1985 (data also reported in Kluwe et al. 1985) 
9 Dog 
(beagle) 
4 M, 4 F 
13 weeks 
5 days/week 
1 time/day 
(C) 
0, 28, 55, 280 BC, BW, CS, 
FI, GN, HE, 
HP, LE, OF, 
OW, UR 
Death   280 2/4 dogs of each sex died 
Bd Wt 55  280 Emaciation, weight loss at 
lethal dose 
Hemato 55 280  Males: decreased hematocrit, 
hemoglobin, RBCs; increased 
lymphocytes 
Females: decreased 
hemoglobin, RBCs, total 
WBCs 
Hepatic 28b M 
55 F 
55 M 280 At 55 mg/kg/day: 22% 
increased liver weight in 
males; bile duct hyperplasia 
(2/4) males 
At 280 mg/kg/day: increased 
liver weight (56% in males, 
77% in females); degenerative 
liver lesions in most males and 
females 
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Table 2-2.  Levels of Significant Exposure to Chlorobenzene – Oral 
Species Less serious Serious 
Figure (strain) Exposure Doses Parameters NOAEL LOAEL LOAEL 
keya No./group parameters (mg/kg/day) monitored Endpoint (mg/kg/day) (mg/kg/day) (mg/kg/day) Effect 
Renal 55 280 Increased kidney weight (62% 
in males, 87% in females); 
degenerative kidney lesions in
most males and females 
Monsanto Co. 1967b
CHRONIC EXPOSURE
10 Rat 103 weeks 0, 60, 120 BW, CS, GN, Death 120 Decreased survival
(F344/N) 5 days/week HP, LE Bd Wt 120
50 M, 50 F 1 time/day 
Hepatic 120(GO)
Renal 120
Cancer 120 CEL: neoplastic liver nodules
NTP 1985 (data also reported in Kluwe et al. 1985)
11 Mouse 103 weeks Males: 0, 30, BW, CS, GN, Bd Wt 60 M 
(B6C3F1)
50 M, 50 F
5 days/week
1 time/day 
(GO)
60
Females: 0, 
60,120
HP, LE 
Hepatic
120 F
60 M 
120 F
Renal 60 M 
120 F
NTP 1985 (data also reported in Kluwe et al. 1985)
aThe number corresponds to entries in Figure 2-3; differences in levels of health effects and cancer effects between male and females are not indicated in 
Figure 2-3.  Where such differences exist, only the levels of effect for the most sensitive gender are presented.
bUsed to derive a provisional intermediate-duration oral MRL of 0.07 mg/kg/day; dose adjusted for intermittent exposure and divided by an uncertainty factor of 
100 (10 for extrapolation from animals to humans and 10 for human variability. 
BC = serum (blood) chemistry; Bd wt or BW = body weight; (C) = capsule; CEL = cancer effect level; CS = clinical signs; Develop = developmental; 
DX = developmental toxicity; F = female(s); FI = food intake; FX = fetal toxicity; (GO) = gavage in oil; GN = gross necropsy; HE = hematology; 
Hemato = hematological; HP = histopathology; Immuno = immunological; LE = lethality; LOAEL = lowest-observed-adverse-effect level; M = male(s); 
MX = maternal toxicity; Neuro = neurological; NOAEL = no-observed-adverse-effect level; OF = organ function; OW = organ weight; RBC = red blood cell; 
TG = teratogenicity; UR = urinalysis; WBC = white blood cell 
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Figure 2-3.  Levels of Significant Exposure to Chlorobenzene – Oral 
Acute (≤14 days) 
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Figure 2-3.  Levels of Significant Exposure to Chlorobenzene – Oral 
Intermediate (15-364 days) 
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Figure 2-3.  Levels of Significant Exposure to Chlorobenzene – Oral 
Chronic (≥365 days) 
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2.2   DEATH 
 
There have been no documented human deaths from chlorobenzene exposure. 
 
The acute lethality of chlorobenzene is relatively low in animals.  Single exposure of mice to 
chlorobenzene vapor at 4,300 ppm for 2 hours resulted in 100% mortality (Rozenbaum et al. 1947).  
Rabbits died 2 weeks after a 2-hour inhalation exposure at approximately 537 ppm (Rozenbaum et al. 
1947).  In a 3-week study of mice exposed to chlorobenzene vapor for 7 hours/day at 543 ppm, death was 
reported in 5/10 mice (Zub 1978).  Death occurred in 3/5 male and 4/5 female rats within 2–3 days 
following a single gavage dose at 4,000 mg/kg; similar exposure of mice resulted in 100% mortality of 
males at 1,000 mg/kg and females at 2,000 mg/kg (NTP 1985).  In a 14-day repeated-dose study of rats, 
gavage exposure at doses ≥1,000 mg/kg resulted in 100% lethality (NTP 1985).  In 13-week repeated-
dose studies, survival was reduced in male and female rats gavaged at doses ≥500 and male and female 
mice gavaged at doses ≥250 mg/kg/day (NTP 1985).  In a 13-week oral study of dogs, ingestion of 
chlorobenzene at 280 mg/kg/day resulted in death of 2/4 dogs of each sex (Monsanto Co. 1967b).  In a 
2-year oral rat study, survival of males at 120 mg/kg/day was significantly lower than that of vehicle 
controls (NTP 1985). 
 
2.3   BODY WEIGHT 
 
No exposure-related effects on body weight were observed in laboratory animals repeatedly exposed to 
chlorobenzene vapor at concentrations as high as 250–590 ppm (Dilley et al. 1977; John et al. 1984; 
Monsanto Co. 1980; Nair et al. 1987).  In a 13-week gavage study, chlorobenzene exposure of male and 
female rats and mice at 250 mg/kg/day (males) and 500 mg/kg/day (females) resulted in 12–20% 
depressed mean final body weight (NTP 1985).  Dogs, which were exposed for 13 weeks to 
chlorobenzene by daily capsule, exhibited emaciation and weight loss at a lethal dose of 280 mg/kg/day 
(Monsanto Co. 1967b). 
 
2.4   RESPIRATORY 
 
Available information regarding chlorobenzene-induced respiratory effects is limited to observations of 
nose rubbing behavior among guinea pigs exposed to chlorobenzene vapor for 30 minutes at a 
concentration as low as 2,990 ppm (Shell Oil Co. 1991). 
 
CHLOROBENZENE  24 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Chlorobenzene has been used as a model VOC in several in vitro studies to investigate possible 
mechanisms of lung inflammation (Feltens et al. 2010; Fischäder et al. 2008; Lehman et al. 2008; Röder-
Stolinski et al. 2008). 
 
2.5   CARDIOVASCULAR 
 
No studies were located regarding cardiovascular effects in humans or laboratory animals exposed to 
chlorobenzene. 
 
2.6   GASTROINTESTINAL 
 
No studies were located regarding gastrointestinal effects in humans or laboratory animals exposed to 
chlorobenzene. 
 
2.7   HEMATOLOGICAL 
 
Information regarding the potential for inhaled chlorobenzene to cause hematological effects is limited.  
In studies of rats and rabbits exposed to chlorobenzene vapor for 7 hours/day, 5 days/week, for up to 
24 weeks at concentrations of 75 or 250 ppm, Dilley (1977) reported exposure concentration-related 
effects on red blood cell parameters (primarily an increase in reticulocyte count).  Other hematological 
parameters (red blood cell count, hemoglobins, hematocrit, and white blood cell count) were variable and 
were comparable to controls at the end of the test.  Zub (1978) reported slight leukopenia and 
lymphocytosis in mice exposed to chlorobenzene for 7 hours/day for 3 months at 21.7 ppm, and similar 
effects in mice similarly exposed for up to 3 weeks at 543 ppm (Zub 1978).  However, limited details in 
the study report and lack of supportive evidence from other animal studies preclude meaningful 
evaluation of chlorobenzene-induced hematological effects following inhalation exposure.  Monsanto Co. 
(1967b) reported changes in selected blood parameters in dogs receiving chlorobenzene in daily capsule 
at 280 mg/kg/day for 13 weeks.  High-dose males exhibited decreases in hematocrit, hemoglobin, and 
RBCs, and increased lymphocytes; high-dose females exhibited decreased in hemoglobin, RBCs, and 
total WBCs. 
 
2.8   MUSCULOSKELETAL 
 
No studies were located regarding musculoskeletal effects in humans or laboratory animals exposed to 
chlorobenzene. 
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2.9   HEPATIC 
 
Available information regarding the potential for chlorobenzene to cause adverse liver effects in humans 
is limited to a single case report in which ingestion of 140 mL of 90% chlorobenzene by a suicidal 
40-year-old, 58-kg, male alcoholic resulted in severe liver necrosis (Babany et al. 1991; Reygagne et al. 
1992).  Although daily alcohol consumption was estimated at approximately 200 g, the patient had no 
history of chronic liver disease.  Serum aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) levels on the third day after chlorobenzene ingestion were 345 and 201 times, respectively, the 
upper limit of normal.  Liver biopsy revealed centrilobular and mediolobular necrosis. 
 
Results from animal studies identify the liver as a target of chlorobenzene toxicity.  In a 2-generation 
inhalation study of rats, repeated inhalation exposure to chlorobenzene vapor at 150 ppm resulted in 
statistically significantly increased mean relative liver weight and increased incidence of hepatocellular 
hypertrophy of parental males (incidence data not included in the study report) (Nair et al. 1987).  In 
several studies that employed repeated gavage exposure to chlorobenzene for up to 3 months, increased 
liver weight was reported in rats at doses as low as 100–250 mg/kg/day (Monsanto Co. 1967a; NTP 
1985), mice at 125 mg/kg/day (NTP 1985), and male dogs at 55 mg/kg/day (Monsanto Co. 1967b).  Two 
of four male dogs treated at 55 mg/kg/day exhibited bile duct hyperplasia (a lesion not observed in control 
dogs); bile duct hyperplasia was noted in 4/4 male and 3/4 female dogs dosed at 280 mg/kg/day 
(Monsanto Co. 1967b).  Hepatic degeneration/necrosis were observed in rats treated at 750 mg/kg/day 
and mice treated at 250 mg/kg/day (NTP 1985).  There were no apparent exposure-related hepatic effects 
among rats or mice administered chlorobenzene by gavage for up to 2 years at doses as high as 60–
120 mg/kg/day (NTP 1985). 
 
2.10   RENAL 
 
Available animal data implicate the kidney as a target of chlorobenzene toxicity.  Nair et al. (1987) 
reported tubular dilatation with eosinophilic material, interstitial nephritis, and foci of regenerative 
epithelium in 2 generations of parental male rats exposed to chlorobenzene vapor at concentrations 
≥150 ppm.  In 3-month repeated-dose gavage studies of rats and mice (NTP 1985), increased kidney 
weight was observed at doses ≥500 mg/kg/day.  Histopathologic kidney lesions (degeneration/focal 
necrosis of the proximal tubules) were observed in rats at 750 mg/kg/day and in mice at doses 
≥250 mg/kg/day (NTP 1985).  Kidney lesions (e.g., tubule dilatation, epithelial degeneration, vacuolation) 
were observed in dogs treated with chlorobenzene in capsules for 13 weeks at 280 mg/kg/day (Monsanto 
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Co. 1967b).  There were no indications of exposure-related kidney effects in rats or mice administered 
chlorobenzene by gavage for up to 2 years at doses as high as 60–120 mg/kg/day (NTP 1985). 
 
2.11   DERMAL 
 
Limited information was located regarding chlorobenzene-induced dermal effects.  There were no signs 
of dermal sensitization in a guinea pig dermal sensitization assay in which chlorobenzene was applied via 
intradermal injection (induction at 1% chlorobenzene), followed by topical induction of a 50% solution 
and two challenge dermal applications of a 25% solution (Miles Inc. 1984). 
 
2.12   OCULAR 
 
Limited information was located regarding chlorobenzene-induced ocular effects.  Lacrimation and 
squinting behavior was observed among rats and guinea pigs exposed to chlorobenzene vapor for 
30 minutes at concentrations ≥2,990 ppm (Shell Oil Co. 1991).  Mild to moderate corneal opacity, iritis, 
redness, chemosis, and discharge were among the effects observed in the eyes of rabbits following ocular 
instillation of chlorobenzene (Zeneca Specialties 1982). 
 
2.13   ENDOCRINE 
 
No studies were located regarding endocrine effects in humans or laboratory animals exposed to 
chlorobenzene. 
 
2.14   IMMUNOLOGICAL 
 
Histological studies in mice and rats suggest that chlorobenzene has immunotoxic properties.  In a 
13-week oral study of rats, gavage exposure at 750 mg/kg/day resulted in myeloid depletion in bone 
marrow and lymphoid depletion in the spleen (NTP 1985).  Similar exposure of mice at doses 
≥250 mg/kg/day resulted in lymphoid depletion/necrosis in the thymus and spleen and myeloid depletion 
in bone marrow of males and lymphoid depletion/necrosis in the spleen of females (NTP 1985).  Since no 
human data were located regarding immunotoxic effects and no animal studies that evaluated immune 
function, firm conclusions can not be made concerning the potential for chlorobenzene to affect the 
immune system in humans. 
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2.15   NEUROLOGICAL 
 
Chlorobenzene affects the central nervous system.  Humans occupationally exposed to chlorobenzene 
intermittently for up to 2 years displayed signs of neurotoxicity including numbness, cyanosis (from 
depression of respiratory center), hyperesthesia, and muscle spasms (Rozenbaum et al. 1947).  Specific 
exposure levels and histopathologic data were not provided in the study report.  When four volunteers 
were exposed via inhalation to 60.2 ppm chlorobenzene for 7 hours during a study of urinary metabolites 
in exposed workers, all complained of disagreeable odor and drowsiness, three complained of headache, 
two of throbbing pain in eyes, and one of sore throat (Ogata et al. 1991).  In addition, mean flicker-fusion 
value declined 3.1 cycles/second in exposed subjects, compared to controls (Ogata et al. 1991). 
 
Neurological effects of chlorobenzene have also been reported in animals following inhalation.  Acute 
inhalation exposure produced muscle spasms followed by narcosis in rabbits exposed to 1,090 ppm 
chlorobenzene for >2 hours (Rozenbaum et al. 1947).  Ataxia and narcosis were observed in rats exposed 
to chlorobenzene vapor for 30 minutes at concentrations ≥5,850 ppm; most rats displayed these effects 
within 25 minutes following initiation of exposure, but they recovered rapidly after removal from the test 
chamber (Shell Oil Co. 1991).  At an exposure concentration of 7,970 ppm, tremors were observed as 
well.  In addition to the narcotic effects observed in the rats, similarly-exposed guinea pigs also exhibited 
salivation at 7,970 ppm. 
 
There is a paucity of data on the effects of chlorobenzene in humans following oral exposure.  A 2-year-
old male swallowed 5–10 cc of a stain remover, which consisted almost entirely of chlorobenzene.  He 
became unconscious, did not respond to skin stimuli, showed muscle spasms, and became cyanotic.  The 
odor of chlorobenzene could be detected in his urine and exhaled air; however, the child recovered 
uneventfully (Reich 1934). 
 
Available information regarding the potential for chlorobenzene to cause neurological effects following 
oral exposure in laboratory animals is limited to findings of decreased activity and prostration among rats 
administered chlorobenzene by gavage once at 4,000 mg/kg/day or repeatedly for 14 days at 
1,000 mg/kg/day; these doses were also lethal (NTP 1985). 
 
2.16   REPRODUCTIVE 
 
No studies were located regarding reproductive effects in humans exposed to chlorobenzene. 
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Limited information is available regarding the potential for chlorobenzene-induced reproductive effects in 
laboratory animals.  In a two-generation study of rats intermittently exposed to chlorobenzene vapor from 
at least 10 weeks prior to mating through lactation of their progeny, increased incidences of degenerative 
testicular changes were observed in males of both generations (6/30 versus 1/30 among controls; 
p=0.051) exposed at 450 ppm (Nair et al. 1987).  The toxicological significance of this finding is unclear 
because mean mating, pregnancy, and male fertility indices for both F0 and F1 generations were 
comparable for all groups. 
 
2.17   DEVELOPMENTAL 
 
No studies were located regarding developmental effects in humans exposed to chlorobenzene. 
 
Limited information is available regarding the potential for chlorobenzene-induced developmental effects 
in laboratory animals.  No indications of chlorobenzene exposure-related developmental effects were 
observed in studies of rats and rabbits exposed to chlorobenzene vapor for 6 hours/day at concentrations 
as high as 590 ppm during gestation days 6–15 (rats) or 6–18 (rabbits) (John et al. 1984).  No indications 
of exposure-related developmental effects were observed in a study of rats administered chlorobenzene by 
daily gavage at doses up to 300 mg/kg/day during gestation days 6–15 (Monsanto Co. 1977). 
 
2.18   OTHER NONCANCER 
 
No studies were located regarding other noncancer effects. 
 
2.19   CANCER 
 
In a chronic oral bioassay in rats and mice (NTP 1985), there was no evidence for carcinogenicity in 
either sex of mice or in female rats administered chlorobenzene in corn oil by gavage at dose levels up to 
120 mg/kg/day.  Increased tumor frequencies were not seen in female rats or in male or female mice.  
Male rats showed a significant (p<0.05) increase in the incidence of neoplastic nodules of the liver in the 
120 mg/kg/day dose group, but no increases were found at lower doses.  While progression from nodules 
to carcinomas is a well-characterized phenomenon, existing data are inadequate to characterize the 
carcinogenic potential of chlorobenzene in humans.  EPA (IRIS 2003) assigned chlorobenzene to class D 
(not classifiable as to human carcinogenicity), based on lack of human data, inadequate animal data, and 
predominantly negative genetic toxicity data in bacterial, yeast, and mouse lymphoma cells. 
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2.20   GENOTOXICITY 
 
No studies were located regarding the genotoxic effects of chlorobenzene in humans.  The potential 
genotoxicity of chlorobenzene has been evaluated in several in vivo studies (Table 2-3) and a greater 
number of in vitro assays (Table 2-4).  Collectively, the results indicate that chlorobenzene is not likely to 
act as a mutagen; however, in vivo results indicate that chlorobenzene may induce other genotoxic effects.  
However, as shown in Figure 3-1, chlorobenzene undergoes CYP450 catalyzed oxidation to form the 
3,4- and 2,3-epoxides of chlorobenzene.  Both epoxides can be formed in liver and lung (and other tissues 
such as kidney and adrenal cortex) and are capable of covalently binding to DNA, RNA, and proteins. 
 
Table 2-3.  Genotoxicity of Chlorobenzene In Vivo 
 
Species (exposure route) Endpoint Results Reference 
Drosophila: 
Male germ cells (airborne 
exposure) 
Sex-linked recessive lethal 
mutations 
– Bioassay Systems Corp. 1982 
Mammalian cells: 
Rat bone marrow 
(intraperiteoneal injection) 
Chromosomal aberrations + Siddiqui et al. 2006 
Mouse bone marrow 
(intraperiteoneal injection) 
Chromosomal aberrations + Mohtashumipur et al. 1987 
Rat bone marrow 
(intraperiteoneal injection) 
Micronuclei + Siddiqui et al. 2006 
Mouse bone marrow 
(intraperiteoneal injection) 
Micronuclei + Mohtashumipur et al. 1987 
Mouse bone marrow 
(intraperiteoneal injection) 
Micronuclei – Shelby and Witt 1995 
Mouse bone marrow 
(intraperiteoneal injection) 
Micronuclei – Shelby et al. 1993 
Mouse peripheral lymphocytes 
(intraperitoneal injection) 
DNA damage + Vaghef and Hellman 1995 
Mouse bone marrow 
(intraperitoneal injection) 
DNA damage – Vaghef and Hellman 1995 
 
+ = positive result; – = negative result; DNA = deoxyribonucleic acid 
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Table 2-4.  Genotoxicity of Chlorobenzene In Vitro 
 
Species (test system) Endpoint 
Results  
With activation Without activation Reference 
Prokaryotic organisms:     
Salmonella typhimurium 
TA98, TA100, TA1535, 
TA1537, TA1538 
Gene mutation – – E.I. Dupont 1977 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
Gene mutation – – Haworth et al. 1983; 
NTP 1985 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
Gene mutation – – Monsanto Co. 
1976b, 1976c 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
Gene mutation – – Shimizu et al. 1983 
Saccharomyces 
cerevisiae D4 
Gene mutation – – Monsanto Co. 
1976b, 1976c 
Eukaryotic organisms:     
Aspergillus nidulans Gene mutation – No data Prasad 1970 
Mammalian cells:     
Mouse L5178Y 
lymphoma cells 
Gene mutation + +/– McGregor et al. 
1988 
Mouse L5178Y 
lymphoma cells 
Gene mutation – – Monsanto Co. 
1976a 
Rat liver epithelial cells Cell 
transformation 
No data + Shimada et al. 1983 
Rat hepatocytes DNA repair No data – Shimada et al. 1983 
Chinese hamster ovary 
cells 
Chromosomal 
aberrations 
– – Bioassay Systems 
Corp. 1982 
Chinese hamster ovary 
cells 
Chromosomal 
aberrations 
– – Loveday et al. 1989 
Chinese hamster ovary 
cells 
Sister chromatid 
exchange 
– + Loveday et al. 1989 
 
+ = positive result; – = negative result; +/– = inconclusive results; DNA = deoxyribonucleic acid 
 
Chlorobenzene did not induce sex-linked recessive lethal mutations in male Drosophila germ cells 
(Bioassay Systems Corp. 1982).  Chlorobenzene induced chromosomal aberrations and micronuclei in 
bone marrow cells in two assays that employed intraperitoneal injection of chlorobenzene into rats and 
mice (Mohtashumipur et al. 1987; Siddiqui et al. 2006), but did not induce micronuclei in mouse bone 
marrow cells in other similarly-designed studies (Shelby and Witt 1995; Shelby et al. 1993).  Vaghef and 
Hellman (1995) reported DNA damage in peripheral lymphocytes from mice following intraperitoneal 
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injection of chlorobenzene for 3 days at 750 mg/kg/day, but no evidence of DNA damage to bone marrow 
cells. 
 
Chlorobenzene did not induce gene mutations either in the presence or absence of exogenous metabolic 
activation in bacterial assays that employed multiple strains of Salmonella typhimurium (E.I. Dupont 
1977; Haworth et al. 1983 [also reported in NTP 1985]; Monsanto Co. 1976a, 1976b; Shimizu et al. 1983) 
or the D4 strain of Saccharomyces cerevisiae (Monsanto Co. 1976b, 1976c).  Chlorobenzene did not 
induce gene mutations in the fungus Aspergillus nidulans in the presence of exogenous metabolic 
activation (Prasad 1970).  Positive results for chlorobenzene-induced gene mutations in mouse L5178Y 
lymphoma cells in the presence and absence of exogenous metabolic activation were obtained in one 
study (McGregor et al. 1988), but not in another study (Monsanto Co. 1976a).  Chlorobenzene induced 
cell transformation in rat liver epithelial cells, but did not induce DNA repair in rat hepatocytes (Shimada 
et al. 1983).  In Chinese hamster ovary cells, negative results were obtained for chromosomal aberrations 
in the presence and absence of exogenous metabolic activation (Bioassay Systems Corp. 1982; Loveday 
et al. 1989), but positive results were obtained for sister chromatic exchange in the absence of exogenous 
metabolic activation (Loveday et al. 1989). 
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CHAPTER 3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, 
BIOMARKERS, CHEMICAL INTERACTIONS 
 
3.1   TOXICOKINETICS  
• Chlorobenzene is readily absorbed from the respiratory and gastrointestinal tracts. 
• Chlorobenzene is widely distributed in the blood, but may accumulate to some extent in adipose 
tissue due to its lipophilicity. 
• Most chlorobenzene is metabolized via a chlorobenzene 3,4-epoxide pathway to ultimate urinary 
glucuronide or sulfate conjugates. 
• Urinary excretion of chlorobenzene metabolites is the major route of excretion. 
 
3.1.1   Absorption  
 
Limited information was located regarding absorption of inhaled chlorobenzene.  Absorption from the 
respiratory tract of two workers exposed to airborne chlorobenzene concentrations in the range of 0.5–
0.84 ppm was estimated to have been 70% (Ogata and Shimada 1983).  In other human studies that 
involved occupational exposure to chlorobenzene, the detection of chlorobenzene metabolites in blood 
and urine provides unquantified demonstration that chlorobenzene is absorbed from the respiratory tract 
(Knecht and Woitowitz 2000; Kumagai and Matsunaga 1994; Kusters and Lauwreys 1990; Ogata et al. 
1991; Yoshida et al. 1986).  Rats were reported to readily absorb 14C-labeled chlorobenzene at airborne 
concentrations up to 700 ppm (Sullivan et al. 1983).  Shimada (1981, 1988) evaluated distribution and 
urinary excretion of chlorobenzene and its metabolites in laboratory animals exposed to chlorobenzene by 
inhalation, thus demonstrating that inhaled chlorobenzene is absorbed. 
 
Chlorobenzene is readily absorbed from the gastrointestinal tract.  Ogata and Shimada (1983) reported at 
least 31% absorption of chlorobenzene orally administered to a single volunteer.  In the same study, rats 
administered chlorobenzene absorbed at least 18% of the administered dose.  Lindsay Smith et al. (1972) 
administered [14C]chlorobenzene to two rabbits orally at approximately 500 mg/rabbit, twice per day for 
4 days and measured radioactivity in urine and feces of both rabbits and tissues of one rabbit.  Recovered 
radioactivity was 19.6% in the urine, 1.05–1.55% in the feces, and 0.05% in tissues; thus, approximately 
20% of the administered dose was absorbed.  The absorption of orally-administered chlorobenzene from 
the gastrointestinal tract was demonstrated in a variety of oral animal studies that were designed to 
evaluate chlorobenzene metabolites in urine (e.g., Azouz et al. 1952; Gillham and Young 1968; Krewet et 
al. 1989; Parke and Williams 1953; Smith et al. 1950, 1972; Spencer and Williams 1950). 
CHLOROBENZENE  33 
 
3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
 
3.1.2   Distribution  
 
Limited information was located regarding distribution of absorbed chlorobenzene in humans.  Knecht 
and Woitowitz (2000) exposed eight volunteers to Germany’s maximum workplace concentration (MAK) 
of 10 ppm chlorobenzene 8 hours/day for 5 days.  There was no apparent tendency for chlorobenzene or 
its metabolites to accumulate in blood or urine with prolonged exposure.  Blood levels reached a steady 
state (mean, 197.0±9.7 µg/L) after the first hour of exposure.  The mean concentration of chlorobenzene 
in blood in five subjects exposed during physical exercise (75 W, 10 minutes/hour on a bicycle) was 
217 µg/L.  In two subjects exposed during mild exercise (50 W, 10 minutes/hour on a bicycle) and one 
subject exposed while at rest, mean blood levels of chlorobenzene were approximately 133 and 78 µg/L, 
respectively. 
 
Studies in laboratory animals indicate that chlorobenzene is widely distributed and may accumulate in 
adipose tissue (Shimada 1988; Sullivan et al. 1983).  Accumulation in adipose tissue is related to the 
lipophilicity of chlorobenzene and likely depends on the species-specific lipid distribution in various 
organs. 
 
3.1.3   Metabolism  
 
A proposed metabolic pathway of chlorobenzene (Chadwick et al. 1984) is shown in Figure 3-1.  The 
numbers 1–16 in Figure 3-1 correspond to the numbers in the following text that presents the various 
metabolic processes. 
 
According to the proposed metabolic pathway, chlorobenzene undergoes CYP450 catalyzed oxidation to 
form chemically-reactive chlorobenzene 3,4-epoxide (1), relatively nontoxic chlorobenzene 2,3-epoxide 
(2) to a lesser extent, and 3 chlorophenol (3).  Both epoxides can be formed in liver and lung (and other 
tissues such as kidney and adrenal cortex) and are capable of covalently binding to DNA, RNA, and 
proteins.  The chlorobenzene epoxides can be further metabolized by three separate pathways.  One 
pathway for 3,4- and 2,3-chlorobenzene epoxides involves the GSH transferase-catalyzed formation of 
glutathione conjugates of 4-chlorophenyl (4) and 2-chlorophenyl (5), respectively, followed by 
conversion to mercapturic acid derivatives.  Another metabolic pathway for the 3,4- and 2,3-epoxides is 
the enzymatic (epoxide hydrase) conversion to 3,4-dihydro-3,4-dihydroxychlorobenzene (6 and 7, 
respectively) which is enzymatically converted to chlorocatechol (8) or chlorophenol (9).  Both 
chlorocatechol and chlorophenol can form glucuronide and sulfate conjugates (10 and 11, respectively).   
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Figure 3-1.  Mammalian Metabolism of Chlorobenzene to Phenols, Dihydrodiols, 
Catechols, and Glutathione Conjugates 
 
 
 
 
Source: Chadwick et al. 1984; reprinted from Pesticide Biochemistry and Physiology 21:148-161 (1984) 
with permission from Elsevier. 
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The 3,4- and 2-3-epoxides can also undergo hydrolysis to form 4-chlorophenol (12) and 2-chlorophenol 
(13), respectively.  The chlorophenols (4-chlorophenol, 3-chlorophenol, and 2-chlorophenol) can form 
glucuronide and sulfate conjugates (14, 15, and 16, respectively). 
 
Chlorobenzene metabolites that have been detected in the urine of a variety of animal species include 2-, 
3-, and 4-chlorophenyl-mercapturic acid, chlorophenols and chlorocatechols and their glucuronide and 
sulfate conjugates, and 3,4-dihydro-3,4-dihydroxychlorobenzene.  Chlorocatechol and 2-chlorophenyl-
mercapturic acid were detected in the urine of humans who received chlorobenzene orally or by 
inhalation (Ogata and Shimada 1983).  Chlorobenzene metabolites that have been detected in the urine of 
chlorobenzene-exposed humans include 4-chlorocatechol, 4-chlorophenol, and 2-chlorophenyl-
mercapturic acid (Kusters and Lauwerys 1990; Ogata and Shimada 1983; Ogata et al. 1991; Yoshida et al. 
1986). 
 
Cytochrome P-450 2E1 is the main enzyme involved in the oxidation of chlorobenzene in mice, rats, and 
humans.  Cytochrome P-450 3A also appears to play a role in the generation of reactive metabolites in 
mice, rats and humans.  It is important to note, however, that, compared to mice and rats, the rate of 
metabolism of chlorobenzene to soluble metabolites is higher in humans, and the formation of covalently 
bound products is lower (Nedelcheva et al. 1998).  In addition, there is up to a 10-fold difference in the 
rate of metabolism of chlorobenzene in different human livers.  There are also significant species and sex 
differences in the metabolism of chlorobenzene with markedly higher rates of oxidation in male mice than 
in male rats and female mice. 
 
Co-treatment of rats with chlorobenzene and an epoxide hydrase inhibitor (cyclohexane oxide) resulted in 
decreases in chlorobenzene metabolism and its necrotic toxicity on the liver, suggesting that the 
metabolism of chlorobenzene is partially responsible for its liver toxicity (Oesch 1973). 
 
3.1.4   Excretion  
 
Knecht and Woitowitz (2000) exposed eight volunteers to Germany’s MAK of 10 ppm chlorobenzene 
8 hours/day for 5 days.  Half-lives of elimination of chlorobenzene from blood were 53 minutes in the 
first hour after cessation of exposure and 150 minutes thereafter.  The major urinary metabolite of 
chlorobenzene was 4-chlorocatechol (74%), with the remainder comprised of chlorophenol isomers of 
which 4-chlorophenol (13%) was the most abundant.  Urinary 4-chlorophenol was useful as a biomarker 
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of exposure due to its half-life of approximately 12 hours.  The elimination half-life of urinary 
4-chlorocatechol was 6.4 hours (Knecht and Woitowitz 2000). 
 
Ogata and Shimada (1983) reported that in two workers exposed by inhalation to 0.84 and 0.5 ppm of 
chlorobenzene, the excretion of 4-chlorophenylmercapturic acid was markedly lower than that of 
4-chlorocatechol.  Ogata and Shimada (1983) also assayed the urinary metabolites of chlorobenzene of a 
57-year-old male volunteer given an oral dose of 0.3 mmol/kg of chlorobenzene.  Two urinary 
metabolites, 4-chlorophenylmercapturic acid and 4-chlorocatechol, were detected.  As in the case of 
inhalation exposure, the excretion of 4-chlorophenylmercapturic acid was reported to be markedly lower 
than that of 4-chlorocatechol.  However, the ratio of mercapturic-acid to 4-chlorocatechol in the urine of 
human subject receiving oral chlorobenzene was similar to that of the two workers inhaling 
chlorobenzene. 
 
Linear correlations between urinary 4-chlorocatechol excretion and airborne exposure of workers to 
chlorobenzene were established by Yoshida et al. (1986) after monitoring end-of-shift urinary metabolites 
in healthy male workers in two chemical factories where chlorobenzene was used as a solvent.  The 
primary urinary metabolites were 4-chlorocatechol (mean 76.9%) and 4-chlorophenol (mean 12.4%).  In 
factories A and B, average chlorobenzene concentrations in air were 3.16 ppm (range 1.72–5.78 ppm) and 
3.14 ppm (range 2.68–3.68 ppm), respectively.  These levels of exposure in factories A and B 
corresponded, respectively, to mean 4-chlorocatechol levels of 0.362 µmoles/mg creatinine (range 0.166–
0.787 µmoles/mg creatinine) and 0.482 µmoles/mg creatinine (range 0.354–0.655 µmoles/mg creatinine) 
in urine (Yoshida et al. 1986). 
 
Assessing 44 maintenance workers in a diphenylmethane 4,4'-diisocyanate plant for chlorobenzene 
exposure, Kusters and Lauwerys (1990) also found that the main urinary metabolites at the end of shift 
were 4-chlorophenol and 4-chlorocatechol, with the latter being 3 times more abundant than the former.  
The time-weighted average exposure to chlorobenzene in air (mean 1.2 ppm, range 0.05–106 ppm) was 
less than the current German MAK value of 10 ppm established in 1995.  More than 80% of the 
metabolites were eliminated within 16 hours after the end of exposure, and there was no tendency for an 
increase in concentration during the working week. 
 
Ogata et al. (1991) reported that, in order of abundance, the main urinary metabolites of chlorobenzene in 
exposed workers were 4-chlorocatechol and 2-chlorophenylmercapturic acid.  The concentrations of 
chlorobenzene in blood and metabolites in urine (e.g., 4-chlorocatechol, approximately 26% of exposure) 
CHLOROBENZENE  37 
 
3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
were both proportional to the concentration of chlorobenzene in air.  The molar ratio of urinary 
chlorocatechol to inhaled chlorobenzene was estimated to be approximately 26%, and the mean slope of 
regression line for chlorobenzene in air versus blood was 4.6±1.15 µg/L for 1 ppm chlorobenzene.  The 
measured biological half-time of 4-chlorocatechol was 2.9 hours. 
 
Rats were exposed to 14C-chlorobenzene vapor at concentrations of 100, 400, and 700 ppm for 8 hours 
(Sullivan et al. 1983).  The plasma concentration-time profile for chlorobenzene on cessation of exposure, 
as estimated by respiratory elimination of radioactivity, indicated a two-compartment elimination.  
Increase in exposure by a factor of 7 (100–700 ppm) increased the total uptake of radioactivity by a factor 
of about 13.  This increase in body burden was associated with a decrease in total body clearance, as 
indicated by an approximate 4-fold increase in the half-life of the central compartment.  The proportion of 
the dose excreted via the lungs (which may be presumed to be largely, if not entirely, unchanged 
chlorobenzene) increased nonlinearly and the proportion eliminated by hepatic metabolism decreased.  
Increase in the dose of chlorobenzene was associated with a decrease in the proportion cleared as the 
mercapturic acid derivative.  Of interest, the half-life of chlorobenzene was shorter at the 700 ppm 
exposure level when the animals were subjected to repeated exposure daily for 5 days, as compared with 
that of the single 700 ppm exposure animals, raising the possibility of induction of metabolic clearance.  
In agreement with this possibility, the proportion cleared by metabolism in the multi-exposed animals was 
increased, and the proportion excreted unchanged via the lung was decreased, as compared with the 
700 ppm-single exposure animals. 
 
In the repeated-dose oral study of rabbits administered [14C]chlorobenzene (Lindsay Smith et al. 1972), 
total recovery of radioactivity from the urine was approximately 20% of the administered dose.  The 
contributions of the various metabolites in the urine were 33.88% for ethereal sulfates, 33.57% for 
glucuronides, 23.8% for mercapturic acids, 4.17% for diphenols, 2.84% for monophenols, and 0.57% for 
3,4-dihydro-3,4-dihydroxychlorobenzene.  It was concluded that the remaining radiolabel was excreted in 
the expired air.  The major urinary metabolites were 4-chlorophenylmercapturic acid and conjugates of 
4-chlorocatechol.  Other identified urinary metabolites included quinol, 3-chlorocatechol, and 2- and 
3-chlorophenylmercapturic acid.  Ogata and Shimada (1983) reported that the primary urinary metabolite 
in rats was 4-chlorophenylmercapturic acid and that 4-chloroatechol was a minor metabolite. 
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3.1.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
PBPK models use mathematical descriptions of the uptake and disposition of chemical substances to 
quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994).  PBPK 
models are also called biologically based tissue dosimetry models.  PBPK models are increasingly used in 
risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that 
will be delivered to any given target tissue following various combinations of route, dose level, and test 
species (Clewell and Andersen 1985).  Physiologically based pharmacodynamic (PBPD) models use 
mathematical descriptions of the dose-response function to quantitatively describe the relationship 
between target tissue dose and toxic endpoints.   
 
Thrall et al. (2004) developed a rat PBPK model for chlorobenzene in air using metabolic data derived 
from groups of F344 male rats exposed to chlorobenzene levels ranging from 82 to 6,750 ppm in air.  
Physiological values (e.g., breathing rate, organ volumes, etc.) were taken from the literature, and 
partition coefficients were determined from in vitro experiments with rat tissues and blood samples.  The 
finished model was evaluated by using it to predict the chlorobenzene levels in exhaled breath of rats 
exposed by corn oil gavage (127 mg/kg) or intraperitoneal injection (131 mg/kg). 
 
A PBPK model was developed to estimate the amount of 19 different VOCs that a nursing infant would 
receive from its occupationally-exposed mother (Fisher et al. 1997).  In a simulation of a lactating woman 
exposed to the threshold limit value (TLV) concentration of chlorobenzene in air at the workplace, the 
amount of chlorobenzene transferred to a nursing infant from mother’s milk was calculated to be 
0.229 mg for a 10-kg infant. 
 
3.1.6   Animal-to-Human Extrapolations  
 
A number of differences between humans and various laboratory animal species preclude meaningful 
extrapolation from animals to humans.  Compared to mice and rats, the rate of metabolism of 
chlorobenzene to soluble metabolites is higher in humans, and the formation of covalently bound products 
is lower (Nedelcheva et al. 1998).  In addition, there is up to a 10-fold difference in the rate of metabolism 
of chlorobenzene in different human livers.  There are also significant species and sex differences in the 
metabolism of chlorobenzene with markedly higher rates of oxidation in male mice than in male rats and 
female mice. 
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3.2   CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans.  Potential effects on offspring resulting from exposures of parental 
germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal 
exposure during gestation and lactation.  Children may be more or less susceptible than adults to health 
effects from exposure to hazardous substances and the relationship may change with developmental age.   
 
This section also discusses unusually susceptible populations.  A susceptible population may exhibit 
different or enhanced responses to certain chemicals than most persons exposed to the same level of these 
chemicals in the environment.  Factors involved with increased susceptibility may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters can reduce detoxification or excretion or compromise organ function.   
 
Populations at greater exposure risk to unusually high exposure levels to chlorobenzene are discussed in 
Section 5.7, Populations with Potentially High Exposures. 
 
No information was located regarding potential differences in susceptibility to chlorobenzene. 
 
3.3   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility 
(NAS/NRC 1989). 
 
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  Biomarkers of 
exposure to chlorobenzene are discussed in Section 3.3.1.  The National Report on Human Exposure to 
Environmental Chemicals provides an ongoing assessment of the exposure of a generalizable sample of 
the U.S. population to environmental chemicals using biomonitoring (see http://www.cdc.gov/
exposurereport/).  If available, biomonitoring data for chlorobenzene from this report are discussed in 
Section 5.6, General Population Exposure.   
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Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that (depending on magnitude) can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effect caused 
by chlorobenzene are discussed in Section 3.3.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.2, Children and Other Populations that are Unusually Susceptible. 
 
3.3.1   Biomarkers of Exposure 
 
Levels of chlorobenzene and its metabolites have been measured in blood, urine, and exhaled air.  Levels 
of 0.05–17 mg/L in the blood and 25–120 µg/L in the urine were detected in samples from residents 
living near a former toxic chemical dump, while trace amounts were found in exhaled air (Barkley et al. 
1980).  Yoshida et al. (1986) demonstrated linear correlations between urinary 4-chlorocatechol excretion 
and airborne exposure of workers to chlorobenzene.  These authors suggested that the former might be an 
effective biomarker of exposure in humans. 
 
Kumagai and Matsunaga (1994, 1995) also found that the major urinary metabolites of chlorobenzene in 
humans, including 4-chlorocatechol (especially) and 4-chlorophenol, are good biomarkers of recent 
exposure in workers.  The slopes of the regression line for urinary metabolite concentration versus 
inhalation exposure concentration do appear to vary somewhat between studies, probably because of 
differences in workloads (active versus at rest) and patterns of exposure (acute versus chronic).  
Nevertheless, controlled chamber studies with workers have demonstrated that the concentrations of both 
major urinary metabolites of chlorobenzene correlate well with workers’ 8-hour time-weighted average 
exposure to chlorobenzene and reflect variations in workplace exposure to chlorobenzene (Kumagai and 
Matsunaga 1995). 
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In an occupational study by Knecht and Woitowitz (2000), the major urinary metabolite of chlorobenzene 
was 4-chlorocatechol (74%).  The remainder consisted of chlorophenol isomers of which 4-chlorophenol 
(13%) was the most abundant.  In spite of its being <20% as abundant as 4-chlorocatechol, urinary 
4-chlorophenol was still considered to be potentially useful as a biomarker of exposure due to its longer 
half-life (approximately 12 hours).  The elimination half-life of urinary 4-chlorocatechol was 6.4 hours. 
 
3.3.2   Biomarkers of Effect 
 
There are no known biomarkers of effect that are specific to chlorobenzene exposure. 
 
3.4   INTERACTIONS WITH OTHER CHEMICALS  
 
In an attempt to identify the proposed epoxide intermediate of chlorobenzene, Oesch (1973) co-
administered the epoxide hydrase inhibitor, cyclohexane oxide, together with chlorobenzene to rats.  
Instead of increasing the toxicity of chlorobenzene as expected, through the inhibition of epoxide hydrase, 
cyclohexane oxide actually decreased the metabolism of chlorobenzene and its necrotic toxicity on the 
liver, suggesting that the metabolism of chlorobenzene is partially responsible for its liver toxicity. 
 
In a mechanistic rat study, a chlorobenzene oral dose of 0.04 mL/180 g (approximately 246 mg/kg) 
caused extensive liver necrosis in rats pretreated with phenobarbital, but little or none in rats that were 
that were not pretreated with phenobarbitol (Brodie et al. 1971).  In another study, the severity of 
chlorobenzene-induced necrosis was decreased by pretreatment with the microsomal enzyme inhibitor, 
SKF 525A.  The authors concluded that reactive metabolites of chlorobenzene that were formed in the 
liver may have subsequently reacted with tissue macromolecules (Brodie et al. 1971).  
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CHAPTER 4.  CHEMICAL AND PHYSICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY 
 
Data pertaining to the chemical identity of chlorobenzene are listed in Table 4-1. 
 
Table 4-1.  Chemical Identity of Chlorobenzene 
 
Characteristic Information Reference 
Chemical name Chlorobenzene NLM 1988 
Synonym(s) and registered 
trade name(s) 
Monochlorobenzene; Benzene chloride; Phenylchloride; 
MCB; Chlorobenzol; Caswell no. 183A 
NLM 1988 
Chemical formula C6H5Cl NLM 1988 
Chemical structure 
 
NLM 1988 
CAS Registry Number  108-90-7 NLM 1988 
 
CAS = Chemical Abstracts Service  
 
4.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
The odor threshold for chlorobenzene in humans has been reported to be as low as 0.21 ppm or 
0.97 mg/m3 (ACGIH 2001; Leonardos et al. 1969).  However, others have reported its “almond-like odor” 
to be “barely perceptible” at 60 ppm (ACGIH 2001; Von Burg 1981; Willhite and Book 1990).  The 
physical and chemical properties of chlorobenzene are presented in Table 4-2. 
 
Table 4-2.  Physical and Chemical Properties of Chlorobenzene 
 
Property Information Reference 
Molecular weight 112.56 Weast 1985 
Color Colorless Verschueren 1983 
Physical state Liquid Verschueren 1983 
Melting point -45.6°C Weast 1985 
Boiling point 132°C Weast 1985 
Density at 20°C 1.1058 Weast 1985 
Odor Aromatic, almond-like Sax and Lewis 1987 
Cl
CHLOROBENZENE  43 
 
4.  CHEMICAL AND PHYSICAL INFORMATION 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 4-2.  Physical and Chemical Properties of Chlorobenzene 
 
Property Information Reference 
Odor threshold: Conflicting data ACGIH 2001 
 Water 0.050 mg/L Verschueren 1983 
 Air 1–8 mg/m3 Verschueren 1983 
Solubility:   
 Water at 20°C 500 mg/L Verschueren 1983 
 Organic solvents Soluble in alcohol, ether, benzene Weast 1985 
Partition coefficients:   
 Log Kow 2.84 Verschueren 1983 
 Log Koc 2.52 Mabey et al. 1982 
Vapor pressure at 20°C 8.8 mmHg Verschueren 1983 
Henry's law constant at 25°C 3.58x10-3 atm-m3/mol Mabey et al. 1982 
Autoignition temperature 637°C Sax and Lewis 1987 
Flashpoint 29.4°C Sax and Lewis 1987 
Flammability limits 1.8–9.6% Sax and Lewis 1987 
Conversion factors 1 ppm=4.7 mg/m3 
1 mg/m3=0.22 ppm 
Verschueren 1983 
Explosive limits 1.3-11 vol% in air) NIOSH 2015 
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CHAPTER 5.  POTENTIAL FOR HUMAN EXPOSURE 
 
5.1   OVERVIEW  
 
Chlorobenzene has been identified in at least 491 of the 1,854 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2017).  However, the number 
of sites in which chlorobenzene has been evaluated is not known.  The number of sites in each state is 
shown in Figure 5-1.  Of these sites, 490 are located within the United States and 1 is located in Puerto 
Rico (not shown). 
 
Figure 5-1.  Number of NPL Sites with Chlorobenzene Contamination 
 
 
• The most likely sources of potential exposure of the general population to chlorobenzene are from 
breathing air, drinking water, or eating food that contain chlorobenzene. 
• Chlorobenzene has been detected in only very small quantities in air, water, and limited food 
sources 
• Chlorobenzene degrades rapidly in air, water, and soil; it is not expected to bioconcentrate. 
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5.2   PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
5.2.1   Production 
 
Production of chlorobenzene in the United States declined by nearly 60%, from the peak production 
volume of 274,000,000 kg in 1960 to 112,000,000 kg in 1987.  This decline is attributed primarily to the 
replacement of chlorobenzene by cumene in phenol production and the cessation of DDT production in 
the United States.  In addition, pesticide production using chlorobenzene as an intermediate has declined 
and no major new uses have been found for chlorobenzene in recent years.  Therefore, the decline in 
chlorobenzene production is expected to continue (EPA 1980c, 1985; Hughes et al. 1983; USITC 1988). 
 
In the 1980s, chlorobenzene was produced by three United States chemical companies: Monsanto 
Chemical Company, Sauget, Illinois; PPG Industries, Inc., Natrium, West Virginia; and Standard 
Chlorine Chemical Co., Inc., Delaware City, Delaware.  Production capacity for chlorobenzene at these 
plants remained constant after 1985, although it appeared that actual production declined slightly during 
that period (Hughes et al. 1983; SRI 1985, 1986, 1987, 1988; USITC 1988). 
 
Chlorobenzene is produced commercially by the chlorination of benzene in the presence of a catalyst 
(e.g., ferric chloride, aluminum chloride, or stannic chloride).  This process yields a mixture of 
chlorobenzene, dichlorobenzenes, and higher analogs, which are distilled and crystallized to obtain pure 
products (EPA 1985a; Hughes et al. 1983). 
 
The Hazardous Substance Data Bank (HSDB) listed the following figures for U.S. production capacity (in 
lbs/year): 368 million in 1990; 371 million in 1993; 370 million in 1996; 358 million in 1999; and 
205 million in 2004.  Assuming a constant annual rate of decline (-3%), production in 2010 was at least 
60% less than in 1990 (HSDB 2011).  Table 5-1 summarizes information on U.S. companies that 
manufactured or used chlorobenzene in 2016 (TRI16 2017). 
 
Table 5-1.  Facilities that Produce, Process, or Use Chlorobenzene 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
AR 4 1,000 999,999 9, 10, 12 
CA 3 100,000 999,999 7, 10, 11 
CO 1 10,000 99,999 10, 11 
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Table 5-1.  Facilities that Produce, Process, or Use Chlorobenzene 
 
Statea 
Number of 
facilities 
Minimum 
amount on site 
in poundsb 
Maximum 
amount on site 
in poundsb Activities and usesc 
GA 1 1,000,000 9,999,999 1, 2, 3, 6, 11 
IA 2 100,000 999,999 7, 10, 11 
IL 1 10,000 99,999 12 
IN 3 100 9,999 9, 12, 14 
KS 2 1,000 999,999 12, 14 
KY 3 10,000 999,999 1, 3, 6, 7, 9 
LA 9 0 9,999,999 1, 4, 5, 6, 7, 9, 10, 11, 12, 13 
MI 2 0 999,999 1, 6, 7, 11, 12, 13, 14 
MO 3 100 99,999 10, 12 
NE 1 10,000 99,999 12 
NY 2 100 99,999 10, 12 
OH 6 1,000 9,999,999 1, 5, 9, 10, 12, 14 
PA 1 1,000 9,999 12 
SC 2 1,000 9,999 12 
TN 1 1,000 9,999 6 
TX 18 1,000 9,999,999 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 14 
UT 1 100,000 999,999 12 
WI 2 0 99,999 6, 12 
 
aPost office state abbreviations used. 
bAmounts on site reported by facilities in each state. 
cActivities/Uses: 
1.  Produce 
2.  Import 
3.  Used Processing 
4.  Sale/Distribution 
5.  Byproduct 
6.  Reactant 
7.  Formulation Component 
8.  Article Component 
9.  Repackaging 
10.  Chemical Processing Aid 
11.  Manufacture Aid 
12.  Ancillary 
13.  Manufacture Impurity 
14.  Process Impurity 
 
Source:  TRI16 2017 (Data are from 2016) 
 
5.2.2   Import/Export 
 
Import and export data for chlorobenzene are not readily available.  Estimates indicated that both imports 
and exports were negligible in the late 1970s and early 1980s (Hughes et al. 1983). 
 
From 2002 to 2003, U.S. exports of chlorobenzene declined from 3.5 million to 1.5 million pounds 
annually.  Imports remained negligible during that time period (HSDB 2011; Kirschner 2004). 
 
CHLOROBENZENE  47 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
5.2.3   Use 
 
Historically, the primary uses of chlorobenzene were as a solvent for pesticide formulations, diisocyanate 
manufacture, degreasing automobile parts, and for the production of nitrochlorobenzene and diphenyl 
oxide.  Solvent uses accounted for about 37% of chlorobenzene consumption in the United States in 1981, 
nitrochlorobenzene production for 33%, and diphenyl oxide and phenylphenol production for 16% of 
consumption.  Chlorobenzene has also been used in silicone resin production and as an intermediate in the 
synthesis of other halogenated organics, including DDT (Hughes et al. 1983).  Recent data regarding 
chlorobenzene uses were not located. 
 
5.2.4   Disposal 
 
Because chlorobenzene is listed as a hazardous substance, disposal of waste chlorobenzene is controlled 
by a number of federal regulations.  Spent solvent wastes, which may include chlorobenzene, are 
prohibited from land disposal, except under specific conditions.  Land disposal restrictions (treatment 
standards) are proposed for other wastes containing chlorobenzene.  Wastes containing chlorobenzene 
may be disposed of by liquid injection, rotary kiln, or fluidized bed incineration (EPA 1988a, 1989b; 
HSDB 1988).  Since chlorobenzene is a volatile compound and is used extensively as a solvent, large 
quantities are released to the air.  Some estimates indicate that 30–50% of the annual production of 
chlorobenzene is released to the atmosphere, while <0.1% is found in waste water and <1% is disposed of 
on land (EPA 1985a). 
 
5.3   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ ≥10 full-time employees; if 
their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 
1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of 
generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or 
oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that 
combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 
(limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 
7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in 
solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes 
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≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar 
year (EPA 2005). 
 
5.3.1   Air  
 
Estimated releases of 403,465 pounds (~183 metric tons) of chlorobenzene to the atmosphere from 
68 domestic manufacturing and processing facilities in 2016, accounted for about 76.1% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI16 2017).  These releases are 
summarized in Table 5-2. 
 
Table 5-2.  Releases to the Environment from Facilities that Produce, Process, or 
Use Chlorobenzenea 
 
 Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri 
Total release 
On-sitej Off-sitek On- and off-site 
AR 4 868 0 0 0 173 868 173 1,040 
CA 3 583 0 0 0 0 583 0 583 
CO 1 266 0 0 0 0 266 0 266 
GA 1 59,246 0 0 0 0 59,246 0 59,246 
IA 2 1,697 0 0 0 0 1,697 0 1,697 
IL 1 2 0 0 12 0 2 12 14 
IN 3 184 0 0 0 0 184 0 184 
KS 2 501 0 0 1,350 750 501 2,100 2,601 
KY 3 376 5 0 0 0 381 0 381 
LA 9 170,321 0 120,000 132 0 290,321 132 290,453 
MI 2 2,043 23 0 51 0 2,107 10 2,117 
MO 3 416 0 0 0 170 416 170 586 
NE 1 33 0 0 199 0 33 199 232 
NY 2 30 0 0 0 0 30 0 30 
OH 6 133,599 9 0 1,671 0 133,608 1,671 135,280 
PA 1 66 0 0 1 0 66 1 66 
SC 2 18 0 0 0 0 18 0 18 
TN 1 0 0 0 0 0 0 0 0 
TX 18 30,637 28 1,158 825 143 30,714 2,077 32,792 
UT 1 13 0 0 4 0 13 4 17 
WI 2 2,567 0 0 0 0 2,567 0 2,567 
Total 68 403,465 65 121,158 4,245 1,236 523,620 6,550 530,170 
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Table 5-2.  Releases to the Environment from Facilities that Produce, Process, or 
Use Chlorobenzenea 
 
 Reported amounts released in pounds per yearb 
Statec RFd Aire Waterf UIg Landh Otheri 
Total release 
On-sitej Off-sitek On- and off-site 
 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 
exhaustive list.  Data are rounded to nearest whole number. 
bData in TRI are maximum amounts released by each facility. 
cPost office state abbreviations are used. 
dNumber of reporting facilities. 
eThe sum of fugitive and point source releases are included in releases to air by a given facility. 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal 
and metal compounds). 
gClass I wells, Class II-V wells, and underground injection. 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills. 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown. 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
 
Source:  TRI16 2017 (Data are from 2016) 
 
5.3.2   Water  
 
Estimated releases of 65 pounds (~0.03 metric tons) of chlorobenzene to surface water from 68 domestic 
manufacturing and processing facilities in 2016, accounted for about 0.01% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI16 2017).  These releases are 
summarized in Table 5-2. 
 
The principal source of chlorobenzene in water is release from chemical manufacturing facilities.  Dow 
Chemical Company estimated that 0.1% of its annual production entered waters (EPA 1980a).  Perry et 
al. (1979) found chlorobenzene in 6/63 industrial effluent in concentrations up to 100 µg/L.  Based on 
1,338 samples collected from about 1980 to 1983, the medium concentration of chlorobenzene in waste 
effluent was <3 ppb and was detected in 54 samples.  The total amount released to the environment was 
not reported (Staples et al. 1985).  Chlorobenzene has been detected in both surface and groundwater 
samples at hazardous waste sites. 
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5.3.3   Soil  
 
Estimated releases of 4,245 pounds (~1.9 metric tons) of chlorobenzene to soil from 68 domestic 
manufacturing and processing facilities in 2016, accounted for about 0.8% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI16 2017).  Estimated releases of 
121,158 pounds (~55 metric tons) of chlorobenzene via underground injection from 68 domestic 
manufacturing and processing facilities in 2016, accounted for about 22.9% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI16 2017).  These releases are 
summarized in Table 5-2. 
 
5.4   ENVIRONMENTAL FATE  
 
5.4.1   Transport and Partitioning  
 
The air, undoubtedly, plays a large role in the environmental transport and degradation of chlorobenzene, 
although studies addressing this aspect were not found.  Chlorobenzene is volatile and has only moderate 
solubility in water (500 mg/L).  Chlorobenzene was observed to evaporate (>99%) from an unaerated 
aqueous solution in 72 hours (Garrison and Hill 1972).  Chlorobenzene is considered sufficiently volatile 
and toxic to pose inhalation risk via vapor intrusion from soil and groundwater (EPA 2018). 
 
5.4.2   Transformation and Degradation  
 
Under hypoxic conditions in groundwater, shifts in the bacterial community may occur as a result of 
syntrophic rather than competitive interactions, facilitating the degradation of chlorobenzene (Kiesel et al. 
2007).  Syntrophy occurs when one organism lives off the product of another organism, rather than the 
organism itself. 
 
Air.    Physical constants for chlorobenzene, especially its vapor pressure and water solubility, indicate 
that the air is an important and perhaps the dominant medium for the transport and transformation of 
chlorobenzene.  As an aromatic molecule with strong UV-absorption, chlorobenzene has a half-life of 20–
40 hours under simulated atmospheric conditions (Dilling et al. 1976).  This appears to be confirmed by 
the large difference between chlorobenzene measurements in urban air (3,000 ng/m3 [0.66 ppb]) and in 
rural air (not detected) in 1982 (Brodzinsky and Singh 1983). 
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Water.    Biodegradation in a waste water inoculum was studied by Tabak et al. (1981).  Among 
57 environmental pollutants tested, chlorobenzene at 5 mg/L (5 ppm) was among the more rapidly 
biodegraded substances with 89% degradation in a week and 100% after adaptation.  Biodegradation is 
therefore a major degradation process in oxygenated waters while evaporation will play an additional role 
in surface waters. 
 
Few data are available from the field, but evaporation, hydrolysis, and microbial degradation, in that 
order, are likely to be the major fates of chlorobenzene discharged to water. 
 
Bioconcentration of chlorobenzene does not appear to be a significant process in aquatic environments.  
However, bioconcentration factors for chlorobenzene do increase somewhat in phytoplankton as 
temperature increases between 4.5 and 27.6°C (Koelmans and Sanchez, 1994). 
 
Oxygen appears to be required for the initial activation of chlorobenzene and the fission of the aromatic 
ring, although it can be partially replaced by nitrate (Nestler et al. 2007). 
 
Metabolic dechlorination of chlorobenzenes seems to proceed fastest under methanogenic conditions 
(Adrian and Görisch 2002; Ramanand et al. 1993).  While the negative changes in Gibbs free energy 
associated with all 20 possible dechlorination reactions of chlorobenzenes are large enough to be coupled 
to adenine triphosphate (ATP) generation, not all of those reactions have been observed in laboratory 
systems, and the extent to which any of them occurs in nature remains unknown (Adrian and Görisch 
2002). 
 
The potential for anaerobic degradation has also been studied in contaminated groundwater plumes, 
where oxygen levels are generally lower than they are outside the plume.  In a study of three North 
Central Florida landfills, Hallbourg et al. (1992) found that due to the high water table, anaerobic 
degradation predominated.  In a contaminated aquifer in Bitterfeld, Germany, the decreases of 
chlorobenzene concentrations at the horizontal fringes of the plume and at shallower depths were 
accompanied by changes in isotopic composition (i.e., enrichment in 13C) that suggested the in situ 
anaerobic degradation of chlorobenzene was occurring, albeit slowly (Kaschl et al. 2005).  Since the 
known aerobic pathway initiated by dioxygenases in chlorobenzene-degrading strains (Ralstonia sp. DSM 
8910, Acidovorax facilis UFZ B517, Rhodococcus erythropolis UFZ B528, and Pseudomonas verinii 
UFZ B547) did not result in isotopic fractionation, it was concluded that a novel anaerobic pathway 
resulting in isotopic fractionation was the predominant process of chlorobenzene degradation in this 
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aquifer.  Chlorobenzene contamination of this aquifer was the likely result of its proximity to a site where 
lindane had been formerly produced; chlorobenzene was measured at up to 30 ppm.  The anaerobic 
microbial degradation of [13C6]-chlorobenzene was confirmed by Nijenhuis et al. (2007).  In a constructed 
wetland designed to treat contaminated groundwater, Braeckevelt et al. (2007a) observed an isotope shift 
that was higher than expected for aerobic chlorobenzene degradation and concluded that an anaerobic 
degradation pathway must be making a significant contribution to the overall degradation.  Natural 
attenuation of 13C-labeled chlorobenzene in this constructed wetland was indicated by: (1) detection of 
13C-labeled (i.e., reductively dechlorinated) benzene; (2) incorporation of chlorobenzene-derived 
radiolabel (13C) into bacterial fatty acids; and (3) a systematic correlation between decreasing 
chlorobenzene concentration and significant enrichment in 13C with increasing distance from the source of 
contamination (Braeckevelt et al. 2007b). 
 
Sediment and Soil.    Biodegradation of chlorobenzene is rapid, leaving no detectable residues after 
1 or 2 weeks.  Adaptation is also rapid (Tabak et al. 1981). 
 
Evaporation and microbial degradation, in that order, are likely to be the major fates of chlorobenzene in 
soils.  However, very few data are available from the field.  Most relevant information comes from 
laboratory studies on amended soils and strains of soil bacteria isolated from contaminated water, soil, or 
sediments. 
 
Under aerobic conditions, all 15 volatile and semivolatile organic compounds (including chlorobenzene) 
in a soil-applied mixture disappeared rapidly during a 7-day observation period due to abiotic factors 
(Anderson et al. 1991).  Feidieker et al. (1995) documented the aerobic degradation of chlorobenzene 
with mixed bacterial cultures.  Complete metabolism of chlorinated benzenes is not a feature that is 
generally found in aerobic bacteria.  However, at chlorobenzene-contaminated sites, indigenous bacteria 
populations appear able to evolve the capacity for natural attenuation of chlorobenzene (Van der Meer et 
al. 1998).  Pseudomonas putida MST that was previously isolated in the presence of α-methylstyrene was 
shown to regioselectively hydroxylate chlorobenzene to 3-chlorocatechol, and 2- and 4-chlorophenol to 
3- and 4-chlorocatechol, respectively (Bestetti et al. 1992).  Inoculation of a soil slurry with Pseudomonas 
aeruginosa (105 microbes/g soil) led to rapid and complete degradation of 0.8 mM chlorobenzene within 
30 hours (Brunsbach and Reineke 1994).  Indigenous soil microbes also degraded chlorobenzene, but the 
higher chlorobenzenes persisted. 
 
CHLOROBENZENE  53 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Chlorobenzene contamination of soil stimulates the growth of indigenous, chlorobenzene metabolizing 
bacteria.  The latter may even out-compete inoculated strains of Pseudomonas (Nishino et al. 1994). 
 
In an in vitro study, Nowak et al. (1996) demonstrated the total reductive dechlorination of 
chlorobenzenes by a methanogenic culture enriched from Saale River sediment.  Dechlorination of 
chlorobenzene to benzene was also observed in these cultures.  However, the amount of benzene formed 
was extremely low and the reaction occurred only in the presence of higher chlorinated benzenes (Nowak 
et al. 1996).  Presumably, this was a co-metabolic process (i.e., one in which the metabolism of 
chlorobenzene occurred without benefit to the organism), but was co-incident with the metabolism of the 
substrate on which the microbe actually depended for energy production.  Such reactions are useful in 
bioremediation because they can proceed at concentrations far below those required to support the 
organism (Hazen 2009). 
 
As previously documented in the field for pesticides and other contaminants, the residue of chlorobenzene 
in soil that is not volatilized or metabolized tends to bind more tightly to soil with time, a phenomenon 
known as “aging” (Sharer et al. 2003).  As a result, degradation occurs at lower rates and to a lesser 
extent, even though chlorobenzene-degrading bacteria still have access to sorbed chlorobenzene in aged 
wetland soils (Lee et al. 2008). 
 
The reductive dechlorination of chlorobenzenes in an anaerobic estuarine sediment followed first-order 
reaction kinetics with rate constants ranging from 0.0016 to 0.0389 day-1 or half-lives between 17 and 
433 days (Kochany and Boltob 1992; Masunaga et al. 1996).  From the detected intermediates, it was 
apparent that the removal of chlorine atoms occurred at all possible positions on the aromatic ring, but 
removal followed a thermodynamically favored order (i.e., a chlorine atom flanked on both sides by 
another > one of two adjacent chlorine atoms > a chlorine with no adjacent chlorine atoms) (e.g., the 
dechlorination of chlorobenzene) (Masunaga et al. 1996). 
 
Other Media.    No studies of chlorobenzene in food or other media were located. 
 
5.5   LEVELS IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to chlorobenzene depends, in part, on the 
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of chlorobenzene in unpolluted atmospheres and in pristine surface waters are often so 
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low as to be near the limits of current analytical methods.  In reviewing data on chlorobenzene levels 
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable. 
 
Table 5-3 shows the lowest limit of detections that are achieved by analytical analysis in environmental 
media.  An overview summary of the range of concentrations detected in environmental media is 
presented in Table 5-4. 
 
Table 5-3.  Lowest Limit of Detection Based on Standardsa 
 
Media Detection limit Reference 
Air 0.47 ppt Krost et al. 1982 
Drinking water 0.01 µg/L (ppb) NEMI 2019 
Surface water and groundwater 0.003 µg/L (ppb) NEMI 2019 
Soil 0.003 µg/L (ppb) NEMI 2019 
Sediment 0.002 ng/mL (ppb) Wolska et al. 2003 
Whole blood 0.011 ng/mL (ppb) CDC 2018 
 
aDetection limits based on using appropriate preparation and analytics.  These limits may not be possible in all 
situations. 
 
Table 5-4.  Summary of Environmental Levels of Chlorobenzene 
 
Media Low High For more information 
Outdoor air (ppbv) 0.022 0.66 Section 5.5.1 
Indoor air (ppbv) No data   
Surface water (ppb) <0.5 <0.5 Section 5.5.2 
Ground water (ppb) <5 <5 Section 5.5.2 
Drinking water (ppb) <5 <5 Section 5.5.2 
Food (ppb) <200 207 Section 5.5.4 
Soil (ppb)  <5 (median value) Section 5.5.3 
 
Detections of chlorobenzene in air, water, and soil at NPL sites are summarized in Table 5-5. 
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Table 5-5.  Chlorobenzene Levels in Water, Soil, and Air of National Priorities List 
(NPL) Sites 
 
Medium Mediana 
Geometric 
meana 
Geometric 
standard 
deviationa 
Number of 
quantitative 
measurements NPL sites 
Water (ppb) 38 73.5 23,400 215 127 
Soil (ppb) 1,550 1,780 84,900 92 64 
Air (ppbv) 1.92 2.66 7,650 28 19 
 
aConcentrations found in ATSDR site documents from 1981 to 2017 for 1,854 NPL sites (ATSDR 2017).  Maximum 
concentrations were abstracted for types of environmental media for which exposure is likely.  Pathways do not 
necessarily involve exposure or levels of concern. 
 
5.5.1   Air  
 
Air samples at 56 localities in the United States in 1982 showed mean chlorobenzene concentrations of 
about 3,000 ng/m3 (0.66 ppb) the highest concentrations were in urban and suburban areas, with much 
lower levels at the sites of production); chlorobenzene was not detectable in rural and remote areas 
(Brodzinsky and Singh 1983).  This suggests not only a substantial contribution to urban air levels by 
small industry and consumer products, but also a short residence time in the air.  A study of New Jersey 
waste sites found similar air levels of chlorobenzene (2,500 ng/m3; 0.55 ppb) (Harkov et al. 1985).  
However, air levels found by another study performed for the EPA (Pellizzari 1978a) were an order of 
magnitude lower, with only the air over a waste site approaching the mean urban concentrations reported 
above.  Ambient air outside homes of "Old Love Canal" (Niagara Falls, New York) contained 
chlorobenzene ranging from not detectable at four sites to traces at four sites and 120 ng/m3 (0.26 ppb) at 
one site (Barkley et al. 1980). 
 
Meek et al. (1994) measured mean concentrations of chlorobenzene that ranged from 0.10 to 0.21 µg/m3 
(0.022–0.046 ppb) in ambient air from 18 Canadian sites in five provinces; corresponding estimated 
intakes in the general population ranged from 0.03 to 0.09 µg/kg/day. 
 
5.5.2   Water  
 
Chlorobenzene, along with other chlorinated chemicals, was found in U.S. rivers at levels up to and 
exceeding 10,000 ng/L (10 ppb) (Shackelford and Keith 1976; Sheldon and Hites 1978).  Private wells 
near a hazardous waste site contained as much as 41 µg/L (41 ppb) (Clark 1982) and tap water at Love 
Canal contained 10–60 ng/L (0.01–0.06 ppb) of chlorobenzene (Barkley et al. 1980). 
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Chlorobenzene contamination of industrial waste waters up to and exceeding 100 µg/L (ppb) was found 
in 6/63 samples (Perry et al. 1979) and in 147/31,194 samples with a mean concentration of 667 µg/L 
(ppb) (EPA 1985a). 
 
Chlorobenzene was generally detected in the low ppb range, when found at all, in three North Central 
Florida landfills (Hallbourg et al. 1992).  Using headspace gas chromatographic analysis with electron 
capture detection (ECD) to avoid the necessity of special cleanup procedures, Först et al. (1993) detected 
an average of 868 ppb chlorobenzene in leachate samples from a highly contaminated landfill.  In the 
early 1990s, chlorobenzene in drinking water was below the limits of detection (1.0 ppb) in 30 different 
locations within Canada (Meek et al. 1994).  Of 2,401 groundwater samples from domestic wells and 
1,096 samples from public wells in a survey in the United States, >90% of the chlorobenzene 
concentrations were <1 ppb and none were as high as 5 ppb (Zogorski et al. 2006). 
 
A risk assessment on chlorobenzene for the marine environment (the North Sea area) was conducted in 
which “risk” was indicated by the ratio of predicted environmental concentration (PEC) to the predicted 
no-effect concentration (PNEC) (set to 32 µg/L [ppb]) for the marine aquatic environment (Van Wijk et 
al. 2004).  Since monitoring data indicated that chlorobenzene in surface waters was below the detection 
limits of 0.1, 0.2, and 0.5 µg/L (ppb), the worst-case PEC was assumed to be 0.5 µg/L (ppb), yielding a 
PEC/PNEC of at least 60, without even taking into account dilution of chlorobenzene-containing surface 
waters in the sea.  The authors concluded that chlorobenzene is not a toxic, persistent, or bioaccumulating 
substance, and that current use of the compound posed no unacceptable risk to the aquatic environment 
(Van Wijk et al. 2004). 
 
5.5.3   Sediment and Soil  
 
Staples et al. (1985) reported that the median concentration of chlorobenzene in the United States was 
estimated to be <5 ppb dry sediments.  In 347 measurements recorded in the STORET database, 2% of 
the samples contained detectable concentrations of chlorobenzene. 
 
5.5.4   Other Media  
 
A national survey of the United States indicated that chlorobenzene was below detection limits in milk 
supplies (Schaum et al. 2003).  Wang and Jones (1994) analyzed carrots, potatoes, cabbage, cauliflower, 
lettuce, onions, beans, peas, and tomatoes for mono- through hexa-chlorobenzenes.  Chlorobenzene was 
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found only in cabbage, at 207 ppb (fresh weight).  Assuming consumption of raw vegetables only, and 
using United Kingdom default consumption rates, chlorobenzene intake via consumption of cabbage was 
estimated to be 850 µg/person/year (Wang and Jones 1994); on this basis, the daily intake for a 70-kg 
adult would be approximately 0.033 µg/kg/day. 
 
5.6   GENERAL POPULATION EXPOSURE  
 
Chlorobenzene was found in 98/100 human adipose tissue samples from all regions of the United States 
at levels ranging from 1 to 9 ng/g (Stanley 1986).  At Love Canal, Niagara Falls, chlorobenzene was 
detected in the breath of one of nine people evaluated for exposure and in the urine of six of nine persons 
at 20–120 ng/L (Barkley et al. 1980). 
 
Personal sampling at chemical companies (Cohen et al. 1981) indicated that chlorobenzene levels, 
measured at up to 4 ppm in work place air did not exceed the American Conference of Governmental 
Industrial Hygienists (ACGIH) and Occupational Safety and Health Administration (OSHA) permissible 
limit of 75 ppm. 
 
According to the results of NHANES IV, chlorobenzene was undetectable in blood samples of every age 
group, gender, race, and ethnicity studied in the survey years between 2003 and 2014 (CDC 2018).  The 
detection limit was 0.011 ng/mL. 
 
5.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
Occupational settings provide the greatest potential for high exposures to chlorobenzene.  Since 
chlorobenzene is a volatile compound and is used extensively as a solvent, large quantities may be 
released to the workplace air.  Other populations that might be exposed include persons living near 
industrial facilities where chlorobenzene emissions are not properly controlled. 
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CHAPTER 6.  ADEQUACY OF THE DATABASE 
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of chlorobenzene is available.  Where adequate information is 
not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the adverse health effects (and techniques for developing methods to 
determine such health effects) of chlorobenzene. 
 
Data needs are defined as substance-specific informational needs that, if met, would reduce the 
uncertainties of human health risk assessment.  This definition should not be interpreted to mean that all 
data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
 
6.1   Information on Health Effects 
 
Studies evaluating the health effects of inhalation, oral, and dermal exposure of humans and animals to 
chlorobenzene that are discussed in Chapter 2 are summarized in Figure 6-1.  The purpose of this figure is 
to illustrate the information concerning the health effects of chlorobenzene.  The number of human and 
animal studies examining each endpoint is indicated regardless of whether an effect was found and the 
quality of the study or studies.   
 
6.2   Identification of Data Needs  
 
Missing information in Figure 6-1 should not be interpreted as a “data need.”  A data need, as defined in 
ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological 
Profiles (ATSDR 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
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Figure 6-1.  Summary of Existing Health Effects Studies on Chlorobenzene By 
Route and Endpoint* 
   
Potential body weight, liver, and kidney effects were the most studied endpoints  
The majority of the studies examined inhalation or oral exposure in animals; limited data were identified 
for humans (counts represent studies examining endpoint) 
 
 
 
 
 
 
 
  
*Includes studies discussed in Chapter 2; the number of studies include those 
finding no effect.  No dermal studies in humans or animals were located. 
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Acute-Duration MRLs.  No information is available on the effects of acute-duration exposure of 
humans to chlorobenzene by any route of exposure.  Limited studies that evaluated the effects of acute-
duration inhalation or oral exposure to chlorobenzene found adverse effects only at exposure levels that 
also caused lethality (Monsanto Co. 1977; NTP 1985; Rozenbaum et al. 1947; Shell Oil Co. 1991).  Since 
data on effects in humans are not available and animal data are mostly limited to lethality, data are not 
sufficient to derive acute-duration MRLs.  Further studies would be useful to identify target tissues and 
threshold levels for effects that may exist. 
 
Intermediate-Duration MRLs.  No studies are available in humans on the effects of intermediate-
duration exposure to chlorobenzene by any route.  Available animal studies identify the nervous system, 
liver, and kidneys as targets of chlorobenzene toxicity.  Oral data were considered adequate to derive a 
provisional intermediate-duration oral MRL for chlorobenzene.  Additional animal studies could be 
designed to provide useful information to serve as basis for deriving an intermediate-duration inhalation 
MRL for chlorobenzene. 
 
Chronic-Duration MRLs.  Limited studies are available on the effects in humans chronically exposed 
to chlorobenzene via inhalation and suggest that nervous system is a target tissue.  Specific exposure data 
were not provided.  No information is available on effects of chlorobenzene in humans following chronic 
oral exposure.  No information is available regarding effects of chlorobenzene in animals following 
chronic-duration inhalation exposure.  One 2-year oral toxicity and carcinogenicity study of rats gavaged 
with chlorobenzene at 60 or 120 mg/kg/day reported decreased survival and increased incidences of 
neoplastic liver lesions at 120 mg/kg/day in the absence of other signs of exposure-related adverse effects 
(NTP 1985).  There were no signs of adverse effects in mice similarly treated at 30 or 60 mg/kg/day 
(males) or 60 or 120 mg/kg/day (females) (NTP 1985).  No nonlethal or nonneoplastic effects were 
observed in rats or mice following chronic-duration oral exposures at doses resulting in adverse 
nonneoplastic effects in animals following intermediate-duration exposures.  Results from intermediate-
duration oral exposure to chlorobenzene indicate that dogs are more sensitive than rats or mice to 
chlorobenzene-induced adverse liver and kidney effects.  The absence of chronic-duration oral data for 
dogs precludes derivation of a chronic-duration oral MRL for chlorobenzene.  A well-designed chronic-
duration oral study in dogs could potentially serve as basis for deriving a chronic-duration oral MRL for 
chlorobenzene. 
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Health Effects.   
 
Hematological Effects.  No data were located regarding the potential for chlorobenzene-
induced renal effects in humans.  Limited animal data are available.  One study reported 
concentration-related effects on red blood cell parameters (primarily an increase in reticulocyte 
count) in rats and rabbits repeatedly exposed to chlorobenzene by inhalation (Dilley 1977).  
Slight leukopenia and lymphocytosis were reported in mice repeatedly exposed by inhalation; 
however, limited details were included in the study report (Zub 1978).  Additional studies could 
be designed to evaluate hematological effects in animals exposed to chlorobenzene. 
 
Hepatic Effects.  Available information regarding the potential for chlorobenzene-induced 
hepatic effects in humans is limited to a single case report of severe liver necrosis in a suicidal 
male alcoholic (Babany et al. 1991; Reygagne et al. 1992).  The liver was identified as a target of 
chlorobenzene toxicity in laboratory animals following inhalation or oral exposure (Monsanto Co. 
1967a, 1967b; Nair et al. 1987; NTP 1985).  No further animal studies are considered necessary. 
 
Renal Effects.  No data were located regarding the potential for chlorobenzene-induced renal 
effects in humans.  The kidney was identified as a target of chlorobenzene toxicity in laboratory 
animals following inhalation or oral exposure (Monsanto Co. 1967b; Nair et al. 1987; NTP 1985).  
No further animal studies are considered necessary. 
 
Immunotoxicity.  No data were located regarding the potential immunotoxicity of 
chlorobenzene in humans.  Histological examination of organs and tissues of the immunological 
system in orally-treated rats and mice resulted in some evidence for the immunotoxicity of 
chlorobenzene (NTP 1985).  Immune function tests would provide a better assessment of 
potential immunotoxic effects. 
 
Neurotoxicity.  Limited data in humans indicate that exposure to chlorobenzene via inhalation 
and oral exposures can result in effects on the nervous system.  Results from one acute-duration 
(30-minute exposure) inhalation study of rats and guinea pigs demonstrate the neurotoxicity of 
inhaled chlorobenzene at very high concentrations (≥2,990 ppm) (Shell Oil Co. 1991).  Oral 
studies in animals could be designed to evaluate the potential neurotoxicity of chlorobenzene by 
this exposure route.  However, it is not likely that oral exposure to chlorobenzene would cause 
neurological effects at environmentally-relevant exposure levels. 
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Reproductive Toxicity.  No studies were regarding the potential reproductive toxicity of 
chlorobenzene in humans.  In a 2-generation oral toxicity study of rats (Nair et al. 1987), 
chlorobenzene gavage exposure of parental males for 18–20 weeks at 450 mg/kg/day resulted in 
increased incidence of testicular germinal epithelial degeneration, but no evidence of impaired 
reproductive function.  There was no evidence of adverse reproductive effects among 
chlorobenzene-treated parental females of either generation at doses as high as 450 mg/kg/day.  
Additional animal studies (including another animal species) could provide additional 
information regarding the potential for chlorobenzene-induced reproductive effects. 
 
Developmental Toxicity.  No data were located regarding the potential developmental toxicity 
of chlorobenzene in humans.  Chlorobenzene did not affect the developing fetus following 
inhalation exposure of rats or rabbits (John et al. 1984) or oral exposure of rats (Monsanto Co. 
1977).  Additional studies do not appear necessary. 
 
Cancer.  No studies were found in humans regarding the carcinogenicity of chlorobenzene.  
Epidemiological studies would be useful to assess potential risk to people who may be 
occupationally exposed to chlorobenzene or people who live near hazardous waste sites where 
chlorobenzene may be present.  There was no evidence for carcinogenicity in both sexes of mice 
or female rats following oral exposure to chlorobenzene.  However, increased incidence of 
neoplastic liver nodules was observed in male rats.  Based on available information from animal 
carcinogenicity studies and genotoxicity evaluations, EPA (IRIS 2003) assigned chlorobenzene to 
group D (not classifiable as to human carcinogenicity).  An additional animal study could be 
designed to further assess the potential carcinogenicity of chlorobenzene.  Although available 
human and animal data have not provided convincing evidence regarding the carcinogenicity of 
chlorobenzene, additional mechanistic studies should be designed to evaluate possible genotoxic 
mechanisms of carcinogenicity because chlorobenzene metabolism results in the formation of 
epoxides that can react with DNA, RNA, and proteins.  Any in vitro assays should be performed 
using human microsomes due to interspecies differences in chlorobenzene metabolism. 
 
Epidemiology and Human Dosimetry Studies.  No epidemiological studies have been conducted 
to evaluate the adverse health effects of chlorobenzene.  Existing studies are limited to case reports of 
occupational exposures in which the nervous system was identified as a target tissue following chronic 
inhalation of chlorobenzene.  Reliable exposure data were not reported.  Additional studies that provide 
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quantitative exposure data would be useful in evaluating potential noncancer and cancer risk in humans 
exposed to chlorobenzene. 
 
Biomarkers of Exposure and Effect.  Parent chlorobenzene and metabolites can be detected in 
biological tissues and fluids.  However, existing methods may not be useful for evaluating the general 
population as opposed to industrial situations where preexposure levels are established prior to known 
chlorobenzene exposure.  The overall reliability of these biomarkers are further reduced since data are not 
available on the half-life of chlorobenzene in various biological media. 
 
Central nervous system injury is a common effect associated with exposure to chlorobenzene vapor in 
humans.  Studies in animals suggest that chlorobenzene can also result in damage to the liver and kidneys.  
Since similar effects occur with exposure to other chemicals, additional studies are needed to identify 
more specific biomarkers by which to monitor populations living near hazardous waste sites. 
 
Absorption, Distribution, Metabolism, and Excretion.  The toxicokinetics of chlorobenzene have 
not been evaluated to any great extent in humans.  Limited studies suggest that chlorobenzene can be 
absorbed following inhalation and oral exposures, but no data were located regarding absorption 
following dermal exposure.  Based on absorption characteristics of benzene and the high lipid solubility 
of chlorobenzene, absorption may be significant depending on conditions.  Additional studies are needed 
to determine absorption rates following exposure by all routes. 
 
Data are also sparse on the distribution of chlorobenzene.  No information is available regarding 
distribution of chlorobenzene in humans by inhalation, oral, or dermal exposure.  Limited animal data 
suggest preferential distribution to adipose tissue in rats via inhalation.  The kidneys and liver also 
showed significant amounts of chlorobenzene and rats that received multiple doses exhibited higher tissue 
burdens than rats exposed only once. 
 
The metabolic transformation of chlorobenzene has been evaluated in humans and animals.  Principal 
metabolites have been determined, but quantities and ratios differ among species.  Additional studies 
would be useful to determine if these differences affect the toxicity of chlorobenzene.  
 
There are limited data on the excretion of chlorobenzene.  In humans exposed via the inhalation and oral 
routes, chlorobenzene and its metabolites were detected in urine and there were differences in excretion 
patterns via the two routes.  Chlorobenzene and its metabolites were also detected in exhaled air of rats 
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following inhalation and in exhaled air and urine of rabbits after oral exposure.  The urinary metabolite 
profile appeared to be dose dependent and there were changes in excretion patterns due to multiple versus 
single exposures.  No data on excretion following dermal exposure are available.  Additional studies 
would be useful in determining the significance of these differences with regard to risk associated with 
different routes of exposure. 
 
Comparative Toxicokinetics.  Although existing studies regarding toxicokinetics of chlorobenzene in 
humans are limited, available data provide some understanding of the absorption, metabolism, and 
excretion following inhalation and oral exposures.  Since studies on distribution of chlorobenzene are 
lacking, quantitative data correlating human exposure and tissue accumulation would be useful.  In 
animals, quantitative data on absorption, distribution, metabolism, and excretion are very limited in extent 
and quality.  Additional studies using a variety of species and including PBPK modeling would be useful 
in determining the most suitable animal model for assessing human risk. 
 
Children’s Susceptibility.  No data were located to suggest age-related differences in susceptibility to 
chlorobenzene toxicity. 
 
Physical and Chemical Properties.  Physical and chemical properties of chlorobenzene have been 
adequately evaluated. 
 
Production, Import/Export, Use, Release, and Disposal.  Data indicate that chlorobenzene 
production has declined dramatically over the past two decades, but current quantitative data on use 
(especially solvent uses) and disposal practices would be helpful in evaluating the effect of current 
industrial practices on environmental levels of chlorobenzene. 
 
Environmental Fate.  Information on biodegradation in soil under aerobic conditions exists, but 
degradation products were not identified.  Anaerobic biodegradation, as might occur in river bottoms and 
in Superfund sites, has not been studied and would be valuable.  Emissions from waste lagoons have been 
modelled and measured in bench-top experiments and are measured as part of many Superfund Remedial 
Investigation/Feasibility studies, but those were not located. 
 
Bioavailability from Environmental Media.  Chlorobenzene is absorbed primarily following 
inhalation of contaminated air.  There is also some potential for exposure from water and soil.  
Chlorobenzene has been detected at low levels in surface, ground, and drinking water, but no information 
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was found on levels in food.  Since chlorobenzene binds tightly to soil particles, skin contact with or 
ingestion of contaminated soil may be an important source of exposure, particularly in children living 
near hazardous waste sites.  Additional studies would be useful to determine if soil-bound chlorobenzene 
is bioavailable. 
 
Food Chain Bioaccumulation.  No information is available regarding biomagnification within 
aquatic or terrestrial food chains.  Additional studies would be useful in assessing potential for human 
exposure to chlorobenzene. 
 
Exposure Levels in Environmental Media.  There are studies on concentrations of chlorobenzene 
in air and water, but many of the samples measured had low levels or did not have detectable levels.  
Additional studies using more sensitive analytical methods would be useful. 
 
Exposure Levels in Humans.  Studies have been conducted measuring chlorobenzene levels in 
drinking water and air (including indoor air).  Conflicting data on chlorobenzene air levels point to a need 
for confirmation and, possibly, validation of analytical methods.  Less conflicting estimates of 
environmental emissions are the prerequisite for any attempt to prioritize control measures. 
 
Exposures of Children.  No data were located to suggest age-related differences in susceptibility to 
chlorobenzene toxicity. 
 
Analytical Methods.  Adequate analytical methods exist to determine chlorobenzene in biological and 
environmental media. 
 
6.3   Ongoing Studies  
 
No ongoing studies were identified for chlorobenzene. 
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CHAPTER 7.  REGULATIONS AND GUIDELINES 
 
Pertinent international and national regulations, advisories, and guidelines regarding chlorobenzene in air, 
water, and other media are summarized in Table 7-1.  This table is not an exhaustive list, and current 
regulations should be verified by referring to the appropriate regulatory agency. 
 
ATSDR develops MRLs, which are substance-specific guidelines intended to serve as screening levels by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.  See Section 1.3 and Appendix A for detailed information on 
the MRLs for chlorobenzene. 
 
Table 7-1.  Regulations and Guidelines Applicable to Chlorobenzene 
 
Agency Description Information Reference 
Air 
EPA RfC No data IRIS 2003 
WHO Air quality guidelines No data WHO 2010 
Water & Food 
EPA Drinking water standards and health advisories  EPA 2012 
 1-Day health advisory (10-kg child) 4 mg/L 
 10-Day health advisory (10-kg child) 4 mg/L 
 DWEL 0.7 mg/L 
 Lifetime health advisory  0.1 mg/L 
 10-4 Cancer risk No data 
National primary drinking water regulations  EPA 2009 
 MCL 0.1 mg/L 
 PHG 0.1 mg/L 
RfD  2x10-2 mg/kg/day EPA 2012; IRIS 
2003 
WHO Drinking water quality guidelines Guideline value not 
establisheda 
WHO 2017 
FDA EAFUS No datab FDA 2013 
Allowable level in bottled water 0.1 mg/L FDA 2017 
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Table 7-1.  Regulations and Guidelines Applicable to Chlorobenzene 
 
Agency Description Information Reference 
Cancer 
ACGIH Carcinogenicity classification A3c ACGIH 2001 
HHS Carcinogenicity classification No data NTP 2016 
EPA Carcinogenicity classification Dd IRIS 2003 
IARC Carcinogenicity classification No data IARC 2017 
Occupational 
ACGIH TLV 10 ppm ACGIH 2001, 
2016 BEI  
 4-Chlorocatecol in urinee,f,g 100 mg/g creatinine 
 p-Chlorophenol in urinee,f,g 20 mg/g creatinine 
OSHA PEL (8-hour TWA) for general industry, 
shipyards and construction 
75 ppm (350 mg/m3)h OSHA 2016a, 
2016b, 2017  
NIOSH REL (up to 10-hour TWA) No datah NIOSH 2016b 
IDLH 1,000 ppm NIOSH 1994 
Emergency Criteria 
EPA AEGLs-air 
 
EPA 2016 
 AEGL 1  
 10-minute 10 ppm 
 30-minute 10 ppm 
 60-minute 10 ppm 
 4-hour 10 ppm 
 8-hour 10 ppm 
 AEGL 2  
 10-minute 430 ppm 
 30-minute 300 ppm 
 60-minute 150 ppm 
 4-hour 150 ppm 
 8-hour 150 ppm 
 AEGL 3  
 10-minute 1,100 ppm 
 30-minute 800 ppm 
 60-minute 400 ppm 
 4-hour 400 ppm 
 8-hour 400 ppm 
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Table 7-1.  Regulations and Guidelines Applicable to Chlorobenzene 
 
Agency Description Information Reference 
DOE PACs-air  DOE 2016b 
 PAC-1i 10 ppm 
 PAC-2i 150 ppm 
 PAC-3i 400 ppm 
 
aReason: occurs in drinking water at concentrations well below those of health concern, and health-based value 
would far exceed lowest reported taste and odor threshold. 
bThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
cGroup A3: confirmed animal carcinogen with unknown relevance to humans. 
dGroup D: not classifiable as to human carcinogenicity. 
eWith hydrolysis. 
fSampling time: end of shift at end of work week. 
gDeterminant is non-specific. 
hAfter reviewing available published literature, NIOSH provided comments to OSHA on August 1, 1988 regarding the 
"Proposed Rule on Air Contaminants" (29 CFR 1910, Docket No. H-020).  In these comments, NIOSH questioned 
whether proposed PELs for certain chemicals including chlorobenzene (TWA 75 ppm) were adequate to protect 
workers from recognized health hazards (NIOSH 2016a). 
iDefinitions of PAC terminology are available from U.S. Department of Energy (DOE 2016a). 
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGLs = acute exposure guideline levels; 
BEI = biological exposure index; DOE = Department of Energy; DWEL = drinking water equivalent level; 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; FDA = Food and 
Drug Administration; GRAS = generally recognized as safe; HHS = Department of Health and Human Services; 
IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; 
IRIS = Integrated Risk Information System; MCL = maximum contaminant level; NIOSH = National Institute for 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 
Administration; PAC = protective action criteria; PEL = permissible exposure limit; PHG = public health goal; 
REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; 
TLV = threshold limit value; TWA = time-weighted average; WHO = World Health Organization 
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APPENDIX A.  ATSDR MINIMAL RISK LEVEL WORKSHEETS 
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the 
most sensitive health effect(s) for a specific duration for a given route of exposure.  An MRL is an 
estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk 
of adverse noncancer health effects over a specified route and duration of exposure.  MRLs are based on 
noncancer health effects only; cancer effects are not considered.  These substance-specific estimates, 
which are intended to serve as screening levels, are used by ATSDR health assessors to identify 
contaminants and potential health effects that may be of concern at hazardous waste sites.  It is important 
to note that MRLs are not intended to define clean-up or action levels. 
MRLs are derived for hazardous substances using the NOAEL/uncertainty factor approach.  They are 
below levels that might cause adverse health effects in the people most sensitive to such chemical-
induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic 
(≥365 days) durations and for the oral and inhalation routes of exposure.  Currently, MRLs for the dermal 
route of exposure are not derived because ATSDR has not yet identified a method suitable for this route 
of exposure.  MRLs are generally based on the most sensitive substance-induced endpoint considered to 
be of relevance to humans.  Serious health effects (such as irreparable damage to the liver or kidneys, or 
birth defects) are not used as a basis for establishing MRLs.  Exposure to a level above the MRL does not 
mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
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Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published MRLs.  
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
S102-1, Atlanta, Georgia 30329-4027. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7
Date: December, 1990
April, 2017—Updated literature search
Profile Status: Final, Draft for Public Comment
Route: Inhalation
Duration: Acute
MRL Summary:  There are insufficient data for derivation of an acute-duration inhalation MRL. 
Rationale for Not Deriving an MRL:  Available information regarding adverse effects following acute-
duration inhalation exposure to chlorobenzene is limited to evaluations of lethality (Rozenbaum et al. 
1947), developmental toxicity studies of rats and rabbits in which no adverse effects were observed at 
exposure concentrations as high as 590 ppm (John et al. 1984), and a study that evaluated effects of a 
single 30-minute exposure at 2,990–7,970 ppm (Shell Oil Co. 1991). 
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7
Date: December, 1990
April, 2017—Updated literature search
Profile Status: Final, Draft for Public Comment
Route: Inhalation
Duration: Intermediate
MRL Summary:  There are insufficient data for derivation of an intermediate-duration inhalation MRL. 
Rationale for Not Deriving an MRL:  Available information regarding the effects of intermediate-
duration inhalation exposure to chlorobenzene is limited.  Chlorobenzene exposure-related liver effects 
(increased liver weight and increased incidence of hepatocellular hypertrophy) and kidney effects (renal 
lesions including chronic interstitial nephritis and foci of regenerative epithelium) were reported for two 
generations of parental male (but not female) rats repeatedly exposed to chlorobenzene vapor at 150 ppm 
(NOAEL of 50 ppm) for 18–20 weeks (Nair et al. 1987).  Dilley (1977) reported significantly increased 
relative liver and kidney weights 31 and 13%, respectively, greater than controls) among rats (but not 
rabbits) repeatedly exposed to chlorobenzene vapor for up to 24 weeks at 250 ppm; however, there were 
no increased incidences of exposure-related histopathological liver or kidney lesions.  Similar exposure of 
rabbits resulted in no significant changes in liver or kidney weight and no evidence of exposure-related 
increased incidence of histopathological liver or kidney lesions.  No effects on liver or kidney were noted 
among dogs repeatedly exposed to chlorobenzene vapor at concentrations as high as 453.2 ppm for up to 
6 months (Monsanto Co. 1980).  No data were located to support the findings of liver and kidney effects 
in the 2-generation study of rats (Nair et al. 1987) at exposure levels as low as 150 ppm.  No intermediate-
duration inhalation MRL was derived for chlorobenzene because intermediate-duration inhalation studies 
of rats and rabbits (Dilley 1977) and dogs (Monsanto Co. 1980) did not identify effects on liver or kidney 
at exposure levels approximately 2–3 times higher than the LOAEL of 150 ppm for parental male rats of 
the 2-generation study (Nair et al. 1987). 
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7
Date: December, 1990
April, 2017—Updated literature search
Profile Status: Final, Draft for Public Comment
Route: Inhalation
Duration: Chronic
MRL Summary:  There are insufficient data for derivation of a chronic-duration inhalation MRL. 
Rationale for Not Deriving an MRL:  No exposure-response human or animal data are available for the 
chronic-duration inhalation exposure to chlorobenzene. 
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7
Date: December, 1990
April, 2017—Updated literature search
Profile Status: Final, Draft for Public Comment
Route: Oral
Duration: Acute
MRL Summary:  There are insufficient data for derivation of an acute-duration oral MRL. 
Rationale for Not Deriving an MRL:  Limited studies that evaluated the effects of acute-duration oral 
exposure to chlorobenzene found adverse effects only at doses that also caused lethality (Monsanto Co. 
1977; NTP 1985). 
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7
Date: December 2019
Profile Status: Final, Draft for Public Comment 
Route: Oral  
Duration: Intermediate 
MRL 0.07 mg/kg/day (provisional)
Critical Effect: Histopathologic liver lesions 
Reference: Monsanto Co. 1967b
Point of Departure: BMDL10 of 9.59 mg/kg/day 
Uncertainty Factor: 100
LSE Graph Key:  9
Species: Dog 
MRL Summary:  A provisional intermediate-duration oral MRL of 0.07 mg/kg/day was derived for 
chlorobenzene based on dose-related hepatic changes in dogs treated orally (via capsule) with 
chlorobenzene 5 days/week for 13 weeks (Monsanto Co. 1967b). The provisional MRL is based on a 
BMDL10 of 9.59 mg/kg/day (BMDL10ADJ of 6.85 mg/kg/day after adjustment for intermittent exposure); a 
total uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability) 
was applied. 
Selection of the Critical Effect:  There are no intermediate-duration oral studies in humans.  Several 
intermediate-duration oral studies are available for rats or mice treated with chlorobenzene by gavage 
(Monsanto Co. 1967a; NTP 1985) or dogs treated via capsule (Monsanto Co. 1967b).  NOAELs and 
LOAELs identified in these studies are summarized in Table A-1.  The effects observed at the lowest 
LOAEL (55 mg/kg/day for liver and kidney effects in dogs) were considered to represent the critical 
effects for deriving a provisional intermediate-duration oral MRL for chlorobenzene.  
Selection of the Principal Study:  The study of Monsanto Co. (1967b) was selected as the principal study 
for deriving a provisional intermediate-duration oral MRL for chlorobenzene because it identified the 
lowest LOAEL of 55 mg/kg/day for increases in liver and kidney weight and increased incidences of 
histopathologic liver and kidney lesions in chlorobenzene-treated dogs (see Table A-1). 
Summary of the Principal Study:
Monsanto.  1967b.  13-week oral administration - dogs:  Monochlorobenzene:  Final report.  Prepared by 
Hazleton Laboratories, Project No. 241-105, February 24.
Groups of beagle dogs (4/sex/group) were treated with chlorobenzene orally (in capsule) at 0, 0.025, 0.05, 
or 0.25 mL/kg/day (0, 28, 55, and 280 mg/kg/day, respectively, based on a density of 1.1058 g/mL for 
chlorobenzene), 5 days/week for 13 weeks.  Dogs were monitored for survival, clinical signs, food intake, 
and body weight.  At study initiation and 1 and 3 months, blood was collected for clinical chemistry and 
hematology and urine was collected for urinalysis.  At death or terminal sacrifice, all animals were 
subjected to gross pathological examination; organ or tissues weighed included heart, liver, spleen, 
kidneys, testes, thyroid, and adrenals.  Selected tissues were processed for histopathologic examination. 
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Table A-1.  Intermediate-Duration Oral NOAELs and LOAELs for Chlorobenzene 
 
Endpoint Species Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Body weight Rat 12% lower mean final body weight 125 M 
250 F 
250 M 
500 F 
NTP 1985 
Rat  250  Monsanto Co. 1967a 
Mouse 15–20% lower mean final body weight 125 M 
250 F 
250 M 
500 F 
NTP 1985 
Dog Emaciation, weight loss at lethal dose 55 280 Monsanto Co. 1967b 
Hematological Rat  250  Monsanto Co. 1967a 
Dog Low hemogram, increased numbers of immature white blood cells 55 280 Monsanto Co. 1967b 
Hepatic Rat 24% (males) and 19% (females) increased liver weight 125 M 
60 F 
250 M 
125 F 
NTP 1985 
Rat 27–29% increased mean relative liver weight 100 250 Monsanto Co. 1967a 
Mouse 125 mg/kg/day: 14% increased liver weight in males 
250 mg/kg/day: 29–35% increased liver weight and hepatic 
necrosis/degeneration both sexes  
60 M 
125 F 
125 M 
250 F 
NTP 1985 
Dog Males: 22% increased liver weight; bile duct hyperplasia (2/4 dogs) 28 55 Monsanto Co. 1967b 
Renal Rat 13–15% increased kidney weight 250 500 NTP 1985 
Rat 13–14% increased kidney weight 100 250 Monsanto Co. 1967a 
Mouse Renal necrosis/degeneration 125 250 NTP 1985 
Dog Increased kidney weight; tubule dilatation, vacuolation, epithelial 
degeneration 
55 280 Monsanto Co. 1967b 
Immunological Rat Myeloid depletion in bone marrow, lymphoid depletion in spleen 500 750 NTP 1985 
 Mouse Males: lymphoid depletion/necrosis in thymus and spleen; myeloid 
depletion in bone marrow 
Females: lymphoid depletion/necrosis in spleen 
125 250 NTP 1985 
 
F = female(s); LOAEL = lowest-observed-adverse-effect level; M = male(s); NOAEL = no-observed-adverse-effect level 
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All dogs in control, 28, and 55 mg/kg/day groups survived to terminal sacrifice.  Four of eight dogs dosed 
at 280 mg/kg/day died or were sacrificed moribund (between weeks 3 and 5).  Decedents exhibited 
decreased appetite, decreased activity, anorexia, and body weight loss.  There were no clear signs of 
exposure-related body weight effects at 28 and 55 mg/kg/day dose levels.  Other effects observed at 
280 mg/kg/day included liver and kidney effects (56–77% increased mean relative liver weight, 62–87% 
increased mean relative kidney weight, increased incidences of pathologic liver and kidney lesions), 
increased adrenal weight, alterations in selected hematological parameters (low hemogram, increased 
numbers of immature white blood cells), increases in selected serum chemistry parameters (low blood 
sugar; increased alkaline phosphatase, ALT, total bilirubin, and total cholesterol), increased urinary 
acetone and bilirubin, and death.  The small numbers of animals (4/sex/group) limit the power to 
determine dose levels resulting in statistically significant changes in liver and kidney lesion incidences.  
However, as shown in Table A-2, the high-dose level (280 mg/kg/day) is an adverse effect level for liver 
effects in males (87% increased mean relative liver weight and centrilobular degeneration and bile duct 
hyperplasia in 4/4 high-dose males; no incidences in controls) and females (62% increased mean relative 
liver weight and centrilobular degeneration in 3/4 high-dose females; no incidences in controls).  Bile 
duct hyperplasia was noted in 2/4 dogs of the 55 mg/kg/day dose group (4/4 males and 3/4 females in the 
280 mg/kg/day dose group, compared to no incidences among control or 28 mg/kg/day groups of males or 
females).  The incidences of bile duct hyperplasia in the 55 mg/kg/day group of male dogs is considered 
to represent a LOAEL for chlorobenzene-induced liver effects because the effect was observed in 2/4 of 
the males treated at 55 mg/kg/day.  Furthermore, after combining sexes, the bile duct hyperplasia 
exhibited a dose-response characteristic (incidences of 3/8 and 7/8 at 55 and 280 mg/kg/day, 
respectively).  The 28 mg/kg/day dose level is considered a NOAEL for liver effects and the 
280 mg/kg/day dose level a serious LOAEL for multiple degenerative liver effects (e.g., centrilobular 
degeneration, vacuolation, bile duct hyperplasia).  As shown in Table A-3, the 280 mg/kg/day dose level 
represents a LOAEL for increased incidences of kidney lesions (e.g., significantly increased incidences of 
tubule dilatation, vacuolation, epithelial degeneration in combined sexes).  The smaller number and nature 
of the reported histopathologic kidney lesions at the low- and mid-dose levels (28 and 55 mg/kg/day) 
and/or lack of dose-response characteristics suggest that the mid-dose (55 mg/kg/day) represents a 
NOAEL for kidney effects. 
 
Table A-2.  Liver Lesion Incidences in Male and Female Dogs (4/Sex/Group) 
Administered Chlorobenzene in Capsule 5 Days/Week for 13 Weeksa 
 
 Chlorobenzene dose (mg/kg/day) 
Control 28 55 280 
Males 
Parenchymal irregularity  3/4 (1) 2/4 (1)  
Chronic hepatitis     
Portal fibrosis  1/4 (1) 1/4 (1)  
Stromal infiltration   2/4 (1)  
Focal leukocyte infiltration  2/4 (1) 1/4 (1)  
Pigment deposition    1/4 (1) 
Extramedullary blood production 1/4 (1)    
Centrilobular degeneration    4/4b (3) 
Vacuolation    3/4 (2–4) 
Bile duct hyperplasia   2/4 (1) 4/4b (+/0–4) 
Cytologic changes   1/4 (1) 2/4 (2–3) 
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Table A-2.  Liver Lesion Incidences in Male and Female Dogs (4/Sex/Group) 
Administered Chlorobenzene in Capsule 5 Days/Week for 13 Weeksa 
 
 Chlorobenzene dose (mg/kg/day) 
Control 28 55 280 
Cloudy swelling   2/4 (1–2)  
Collangitis    1/4 (2) 
Bile stasis    2/4 (1–3) 
Females 
Parenchymal irregularity   3/4 (1)  
Chronic hepatitis 1/4 (1)    
Portal fibrosis     
Stromal infiltration 1/4 (1)  1/4 (1)  
Focal leukocyte infiltration     
Pigment deposition  1/4 (1)  2/4 (1–2) 
Extramedullary blood production 1/4 (1)    
Centrilobular degeneration    4/4b (1–3) 
Vacuolation   1/4 (1) 3/4 (1–3) 
Bile duct hyperplasia   1/4 (1) 3/4 (1) 
Cytologic changes    2/4 (1–2) 
Cloudy swelling   1/4 (1)  
Collangitis    1/4 (1) 
Bile stasis    2/4 (3) 
Combined sexes 
Parenchymal irregularity  3/8 (1) 5/8b (1)  
Chronic hepatitis 1/8 (1)    
Portal fibrosis  1/8 (1) 1/8 (1)  
Stromal infiltration 1/8 (1)  3/8 (1)  
Focal leukocyte infiltration  2/8 (1) 1/8 (1)  
Pigment deposition  1/8 (1)  3/8 (1–2) 
Extramedullary blood production 2/8 (1)    
Centrilobular degeneration    8/8b (1–3) 
Vacuolation   1/8 (1) 6/8b (1–4) 
Bile duct hyperplasia   3/8 (1) 7/8b (+/0–4) 
Cytologic changes   1/8 (1) 4/8b (1–3) 
Cloudy swelling   3/8 (1–2)  
Collangitis    2/8 (1–2) 
Bile stasis    4/8b (1–3) 
 
aNumbers in parentheses denote relative severity of lesion (4 represents highest degree of severity). 
bSignificantly different from control incidence (p<0.05). 
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Table A-3.  Kidney Lesion Incidences in Male and Female Dogs (4/Sex/Group) 
Administered Chlorobenzene in Capsule 5 Days/Week for 13 Weeksa 
 
 Chlorobenzene dose (mg/kg/day) 
Control 28 55 280 
Males 
Pelvic epithelial irregularity  2/4 (1–2)   
Terminal proximal tubule swelling 3/4 (2) 3/4 (1–3) 3/4 (3) 1/4 (3) 
Terminal proximal tubule vacuolation  1/4 (1)   
Tubule dilatation   1/4 (1) 2/4 (1–2) 
Tubule epithelial degeneration   1/4 (1) 1/4 (2) 
Proximal convoluted tubule swelling    1/4 (1) 
Proximal convoluted tubule vacuolation    1/4 (1) 
Glomerular swelling    1/4 (2) 
Glomerulosclerosis 1/4 (1)  1/4 (1) 1/4 (1) 
Chronic pyelitis  1/4 (1)   
Intraluminal foreign matter     
Epithelial pigment deposition    2/4 (2–3) 
Females 
Pelvic epithelial irregularity 1/4 (2)    
Terminal proximal tubule swelling    1/4 (1) 
Terminal proximal tubule vacuolation    2/4 (4) 
Tubule dilatation   1/4 (1) 2/4 (2) 
Tubule epithelial degeneration    3/4 (1–3) 
Proximal convoluted tubule swelling    1/4 (1) 
Proximal convoluted tubule vacuolation   1/4 (1) 3/4 (2–3) 
Glomerular swelling     
Glomerulosclerosis 1/4 (1) 4/4 (1) 3/4 (1)  
Chronic pyelitis 2/4 (2–3)  1/4 (2)  
Intraluminal foreign matter    1/4 (1) 
Epithelial pigment deposition    1/4 (+/0) 
Combined sexes 
Pelvic epithelial irregularity 1/8 (2) 2/8 (1–2)   
Terminal proximal tubule swelling  3/8 (1–3) 3/8 (3) 2/8 (1 or 3) 
Terminal proximal tubule vacuolation  1/8 (1)  2/8 (4) 
Tubule dilatation   2/8 (1) 4/8b (1–2) 
Tubule epithelial degeneration   2/8 (1) 4/8b (1–3) 
Proximal convoluted tubule swelling    2/8 (1) 
Proximal convoluted tubule vacuolation   1/8 (1) 4/8b (2–3) 
Glomerular swelling    1/8 (2) 
Glomerulosclerosis 2/8 (1) 4/8 (1) 4/8 (1) 1/8 (1) 
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Table A-3.  Kidney Lesion Incidences in Male and Female Dogs (4/Sex/Group) 
Administered Chlorobenzene in Capsule 5 Days/Week for 13 Weeksa 
 
 Chlorobenzene dose (mg/kg/day) 
Control 28 55 280 
Chronic pyelitis 2/8 (2–3) 1/8 (1) 1/8 (2)  
Intraluminal foreign matter    1/8 (1) 
Epithelial pigment deposition 1/4 (1)   3/8 (+/0–3) 
 
aNumbers in parentheses denote relative severity of lesion (4 represents highest degree of severity). 
bSignificantly different from control incidence(p<0.05). 
 
Selection of the Point of Departure:  Among available rat, mouse, and dog studies that employed 
intermediate-duration oral exposure, the lowest LOAEL is 55 mg/kg/day for liver effects in the dogs; the 
corresponding NOAEL is 28 mg/kg/day.  Because the study employed only four dogs/sex/group, results 
for each sex were combined for each reported liver lesion type.  The dataset for bile duct hyperplasia for 
combined sexes (see Table A-4) was considered adequate for benchmark dose (BMD) analysis.  The data 
were fit to all available dichotomous models in EPA’s Benchmark Dose Software (BMDS, version 
2.6.0.1) using the extra risk option.  A benchmark response (BMR) of 10% over the control incidence was 
used.  Adequate model fit was judged by three criteria:  goodness-of-fit statistics (p-value >0.1), visual 
inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to 
the predefined BMR. 
 
The model predictions are presented in Table A-5.  Among all models providing adequate fit to the data, 
the lowest BMDL (Multistage 1-degree model) was selected as the point of departure because the 
difference between the BMDLs estimated from these models was >3-fold.  The fit of the Multistage 
1-degree model is presented in Figure A-1. 
 
Table A-4.  Dataset for BMD Analysis of Bile Duct Hyperplasia Incidences in Male 
and Female Dogs Administered Chlorobenzene in Capsule for 13 Weeksa 
 
 Chlorobenzene dose (mg/kg/day) 
Control 28 55 280 
Males 0/4 0/4 2/4 (1) 4/4b  
Females 0/4 0/4 1/4 (1) 3/4 (1) 
Males and females (combined) 0/8 0/8 3/8 (1) 7/8b (+/0–4) 
 
aNumbers in parentheses denote relative severity of lesion (4 represents highest degree of severity). 
bSignificantly different from control incidence (p<0.05). 
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Table A-5.  Model Predictions for Bile Duct Hyperplasia in Dogs Administered 
Chlorobenzene in Capsule for 13 Weeks  
Model DF χ2 
χ2 
Goodness 
of fit 
p-valuea 
Scaled residualsb 
AIC 
BMD10 
(mg/kg/day) 
BMDL10 
(mg/kg/day) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
 
Gammac 2 1.78 0.41 -0.91 0.94 0.94 23.05 29.15 10.37 
Logistic 2 4.27 0.12 -1.00 1.61 1.61 25.77 54.72 30.85 
LogLogisticd 2 1.36 0.51 -0.84 0.74 -0.84 22.57 31.35 11.08 
LogProbitd 2 1.30 0.52 -0.77 0.78 0.78 22.41 32.93 17.04 
Multistage (1-degree)e,f 3 1.90 0.59 0.00 -1.26 -1.26 21.81 16.41 9.59 
Multistage (2-degree)e 2 1.93 0.38 0.00 -1.05 -1.05 23.43 23.07 9.96 
Multistage (3-degree)e 2 1.93 0.38 0.00 -1.05 -1.05 23.43 23.07 9.96 
Probit 2 4.20 0.12 -0.96 1.64 1.64 25.55 52.18 31.71 
Weibullc 2 1.83 0.40 0.00 -0.97 -0.97 23.20 26.73 10.20 
 
aValues <0.1 fail to meet conventional goodness-of-fit criteria. 
bScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose. 
cPower restricted to ≥1. 
dSlope restricted to ≥1. 
eBetas restricted to ≥0. 
fSelected model.  All models provided adequate fit to the data.  BMDLs for models providing adequate fit were not 
sufficiently close (differed by >3-fold).  Therefore, the model with lowest BMDL was selected (Multistage 1-degree). 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL10 = 95% lower confidence limit on the BMD for a benchmark response 
of 10% extra risk; DF = degrees of freedom  
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Figure A-1.  Fit of 1-Degree Multistage Model for Bile Duct Hyperplasia Incidence 
Data for Dogs (Combined Sexes) Administered Chlorobenzene by Capsule 
(Dose in mg/kg/day) for 13 Weeks 
 
 
Selected kidney lesion data (tubule dilatation, tubule epithelial degeneration, and proximal convoluted 
tubule vacuolation) for combined sexes were also considered for MRL derivation (see Table A-6) because 
they exhibited some evidence of dose-response characteristics and statistically significantly increased 
incidences for these lesions were observed at the highest dose (280 mg/kg/day).  Each dataset was fit to 
all available dichotomous models in EPA’s BMDS (version 2.6.0.1) using the BMD approach described 
for the liver lesion data above. 
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Table A-6.  Dataset for BMD Analysis of Selected Kidney Lesion Incidences in 
Dogs Administered Chlorobenzene in Capsule for 13 Weeksa 
Control 
Chlorobenzene dose (mg/kg/day)
28 55 280 
Tubule dilatation
Males 
Females 
Males and females (combined)
Males 
Females 
Males and females (combined)
0/4 0/4 1/4 (1)
0/4 0/4 1/4 (1)
0/8 0/8 2/8 (1)
Tubule epithelial degeneration
0/4 0/4 1/4 (1)
0/4 0/4 0/4 
0/8 0/8 2/8 (1)
Proximal convoluted tubule vacuolation
 2/4  (1-2)
 2/4  (2)
 4/8b (1–2)
 1/4  (2)
3/4 (1–3)
 4/8b (1–3)
Males 
Females 
Males and females (combined)
0/4 
0/4 
0/8 
0/4 
0/4 
0/8 
0/4 
1/4 (1)
1/8 (1)
1/4 (1)
 3/4  (2–3)
 4/8b (1–3)
aNumbers in parentheses denote relative severity of lesion (4 represents highest degree of severity). 
bSignificantly different from control incidence (p<0.05).
All models provided adequate fit to each dataset for kidney lesions.  For both tubule dilatation and tubule 
epithelial degeneration, the best-fitting model provided a BMD10 of 37.71 mg/kg/day and a BMDL10 of
14.07 mg/kg/day.  For proximal convoluted tubule vacuolation, the best-fitting model provided a BMD10 
of 63.80 mg/kg/day and a BMDL10 of 19.73 mg/kg/day.  The most health protective point of departure for 
deriving a provisional intermediate-duration oral MRL for chlorobenzene is the BMDL10 of 
9.59 mg/kg/day for bile duct hyperplasia because it is lower than the NOAEL of 28 mg/kg/day for liver 
effects and lower than potential points of departure based on kidney effects (BMDL10 values of 14.07 and 
19.73 mg/kg/day and NOAEL of 55 mg/kg/day).
Intermittent Exposure:  The BMDL10 of 9.59 mg/kg/day in orally-treated dogs was adjusted from 
intermittent exposure (5 days/week): 
9.59 mg/kg/day x 5 days/7 days = BMDL10ADJ of 6.85 mg/kg/day
Uncertainty Factor: The BMDL10ADJ was divided by a total uncertainty factor of 100:
 10 for extrapolation from animals to humans
 10 for human variability 
Provisional MRL = BMDL10ADJ ÷ UFs 
6.85 mg/kg/day ÷ (10 x 10) = 0.07 mg/kg/day (rounded up from 0.0685 mg/kg/day) 
Other Additional Studies or Pertinent Information that Lend Support:  As shown in Table A-1, liver 
and kidney effects were observed in rats and mice treated orally with chlorobenzene for intermediate-
duration periods (Monsanto Co. 1967a; NTP 1985).
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D.
***DRAFT FOR PUBLIC COMMENT*** 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlorobenzene 
CAS Numbers: 108-90-7 
Date: December, 1990 
 April, 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Chronic 
 
MRL Summary:  There are insufficient data for derivation of a chronic-duration oral MRL. 
 
Rationale for Not Deriving an MRL:  One 2-year oral toxicity and carcinogenicity study of rats gavaged 
with chlorobenzene at 60 or 120 mg/kg/day reported decreased survival and increased incidences of 
neoplastic liver lesions at 120 mg/kg/day in the absence of other signs of exposure-related adverse effects 
(NTP 1985).  There were no signs of adverse effects in mice similarly treated at 30 or 60 mg/kg/day 
(males) or 60 or 120 mg/kg/day (females) (NTP 1985).  No nonlethal and nonneoplastic effects were 
observed in the rats or mice following chronic-duration oral exposures at doses resulting in adverse 
nonneoplastic effects in animals following intermediate-duration exposures.  Therefore, no chronic-
duration oral MRL was derived for chlorobenzene. 
 
EPA (IRIS 2003) derived a chronic RfD of 0.02 mg/kg/day for chlorobenzene based on histopathologic 
changes in the liver of dogs administered chlorobenzene in daily capsule for 13 weeks (the same critical 
effect employed by ATSDR to derive a provisional intermediate-duration oral MRL).  EPA included an 
uncertainty factor of 10 to account for extrapolation from the 13-week exposure to a chronic exposure 
scenario.  It is not standard policy for ATSDR to extrapolate from an intermediate-duration exposure 
protocol to a chronic-duration exposure protocol in the absence of adequate chronic-duration data. 
 
Agency Contacts (Chemical Managers):  G. Daniel Todd, Ph.D. 
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APPENDIX B.  LITERATURE SEARCH FRAMEWORK FOR 
CHLOROBENZENE 
 
The objective of the toxicological profile is to evaluate the potential for human exposure and the potential 
health hazards associated with inhalation, oral, or dermal/ocular exposure to chlorobenzene.   
 
B.1  LITERATURE SEARCH AND SCREEN  
 
A literature search and screen was conducted to identify studies examining health effects, toxicokinetics, 
mechanisms of action, susceptible populations, and biomarkers for chlorobenzene.  ATSDR primarily 
focused on peer-reviewed articles without publication date or language restrictions.  Non-peer-reviewed 
studies that were considered relevant to the assessment of the health effects of chlorobenzene have 
undergone peer review by at least three ATSDR-selected experts who have been screened for conflict of 
interest.  The inclusion criteria used to identify relevant studies examining the health effects of 
chlorobenzene are presented in Table B-1. 
 
Table B-1.  Inclusion Criteria for the Literature Search and Screen 
 
Health Effects 
 Species 
  Human 
  Laboratory mammals 
 Route of exposure 
  Inhalation 
  Oral 
  Dermal (or ocular) 
  Parenteral (these studies will be considered supporting data) 
 Health outcome 
  Death 
  Systemic effects 
  Body weight effects  
  Respiratory effects 
  Cardiovascular effects 
  Gastrointestinal effects 
  Hematological effects 
  Musculoskeletal effects 
  Hepatic effects 
  Renal effects 
  Dermal effects 
  Ocular effects 
  Endocrine effects 
  Immunological effects 
  Neurological effects 
  Reproductive effects 
  Developmental effects 
  Other noncancer effects 
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Table B-1.  Inclusion Criteria for the Literature Search and Screen 
 
  Cancer 
Toxicokinetics 
 Absorption 
 Distribution 
 Metabolism 
 Excretion 
 PBPK models 
Biomarkers 
 Biomarkers of exposure 
 Biomarkers of effect 
Interactions with other chemicals 
 
B.1.1  Literature Search 
 
The current literature search was intended to update the health effects sections of the existing 
toxicological profile for chlorobenzene (ATSDR 1990), thus, the literature search was restricted to studies 
published between January 1988 to April 2017.  The following main databases were searched in April 
2017: 
 
• PubMed  
• National Library of Medicine's TOXLINE 
• Scientific and Technical Information Network's TOXCENTER 
 
The search strategy used the chemical names, Chemical Abstracts Service (CAS) numbers, 
synonyms, Medical Subject Headings (MeSH) headings, and keywords for chlorobenzene.  The 
query strings used for the literature search are presented in Table B-2. 
 
The search was augmented by searching the Toxic Substances Control Act Test Submissions (TSCATS), 
NTP website, and National Institute of Health Research Portfolio Online Reporting Tools Expenditures 
and Results (NIH RePORTER) databases using the queries presented in Table B-3.  Additional databases 
were searched in the creation of various tables and figures, such as the TRI Explorer, the Substance 
Priority List (SPL) resource page, and other items as needed.  Regulations applicable to chlorobenzene 
were identified by searching international and U.S. agency websites and documents. 
 
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and 
abstracts, and theses and dissertations.   
 
Table B-2.  Database Query Strings  
 
Database 
search date Query string 
PubMed  
04/2017 (((108-90-7[rn] OR K18102WN1G[rn] OR chlorobenzene[supplementary concept] OR 
chlorobenzene[nm]) AND (1988/01/01 : 3000[dp] OR 1988/01/01 : 3000[mhda])) OR 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
((("Benzene chloride"[tw] OR "Chloorbenzeen"[tw] OR "Chlorbenzene"[tw] OR 
"Chlorbenzol"[tw] OR "Chlorobenzen"[tw] OR "Chlorobenzene"[tw] OR "mono-
Chlorobenzene "[tw] OR "Chlorobenzenu"[tw] OR "Chlorobenzol"[tw] OR 
"Clorobenzene"[tw] OR "I P Carrier T 40"[tw] OR "Monochloorbenzeen"[tw] OR 
"Monochlorbenzene"[tw] OR "Monochlorbenzol"[tw] OR "Monochlorobenzene"[tw] OR 
"Monoclorobenzene"[tw] OR "Phenyl chloride"[tw] OR "Tetrosin SP"[tw]) AND (1988/01/01 
: 3000[dp] OR 1988/01/01 : 3000[crdat] OR 1988/01/01 : 3000[edat])) AND (to[sh] OR 
po[sh] OR ae[sh] OR pk[sh] OR (me[sh] AND ("humans"[mh] OR "animals"[mh])) OR ci[sh] 
OR bl[sh] OR cf[sh] OR ur[sh] OR "environmental exposure"[mh] OR "endocrine 
system"[mh] OR "hormones, hormone substitutes, and hormone antagonists"[mh] OR 
"endocrine disruptors"[mh] OR (("Computational biology"[mh] OR "Medical 
Informatics"[mh] OR Genomics[mh] OR Genome[mh] OR Proteomics[mh] OR 
Proteome[mh] OR Metabolomics[mh] OR Metabolome[mh] OR Genes[mh] OR "Gene 
expression"[mh] OR Phenotype[mh] OR genetics[mh] OR genotype[mh] OR 
Transcriptome[mh] OR ("Systems Biology"[mh] AND ("Environmental Exposure"[mh] OR 
"Epidemiological Monitoring"[mh] OR analysis[sh])) OR "Transcription, Genetic "[mh] OR 
"Reverse transcription"[mh] OR "Transcriptional activation"[mh] OR "Transcription 
factors"[mh] OR ("biosynthesis"[sh] AND (RNA[mh] OR DNA[mh])) OR "RNA, 
Messenger"[mh] OR "RNA, Transfer"[mh] OR "peptide biosynthesis"[mh] OR "protein 
biosynthesis"[mh] OR "Reverse Transcriptase Polymerase Chain Reaction"[mh] OR "Base 
Sequence"[mh] OR "Trans-activators"[mh] OR "Gene Expression Profiling"[mh])) OR 
cancer[sb] OR "pharmacology"[sh:noexp] OR toxicokinetics[mh:noexp]))) OR ((("Benzene 
chloride"[tw] OR "Chloorbenzeen"[tw] OR "Chlorbenzene"[tw] OR "Chlorbenzol"[tw] OR 
"Chlorobenzen"[tw] OR "Chlorobenzene"[tw] OR "mono-Chlorobenzene "[tw] OR 
"Chlorobenzenu"[tw] OR "Chlorobenzol"[tw] OR "Clorobenzene"[tw] OR "I P Carrier T 
40"[tw] OR "Monochloorbenzeen"[tw] OR "Monochlorbenzene"[tw] OR 
"Monochlorbenzol"[tw] OR "Monochlorobenzene"[tw] OR "Monoclorobenzene"[tw] OR 
"Phenyl chloride"[tw] OR "Tetrosin SP"[tw]) AND (1988/01/01 : 3000[dp] OR 1988/01/01 : 
3000[crdat] OR 1988/01/01 : 3000[edat])) NOT medline[sb]) 
Toxline  
04/2017 ( "benzene chloride" OR "chloorbenzeen" OR "chlorbenzene" OR "chlorbenzol" OR 
"chlorobenzen" OR "chlorobenzene" OR "mono-chlorobenzene " OR "chlorobenzenu" OR 
"chlorobenzol" OR "clorobenzene" OR "i p carrier t 40" OR "monochloorbenzeen" OR 
"monochlorbenzene" OR "monochlorbenzol" OR "monochlorobenzene" OR 
"monoclorobenzene" OR "phenyl chloride" OR "tetrosin sp" OR 108-90-7 [rn] ) AND 
1988:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR 
EMIC [org] OR EPIDEM [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE 
[org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] 
) AND NOT PubMed [org] AND NOT pubdart [org] 
Toxcenter  
04/2017      FILE 'TOXCENTER' ENTERED AT 16:05:42 ON 06 APR 2017 
L1         8321 SEA 108-90-7  
L2         8083 SEA L1 NOT TSCATS/FS  
L3         6982 SEA L2 NOT PATENT/DT  
L4         5631 SEA L3 AND PY>=1988  
                ACTIVATE TOXQUERY/Q 
               --------- 
L5              QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR  
                BIOMARKER? OR NEUROLOG?)  
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
L6              QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR  
EPIDEMIOLOGY/ST,CT, 
                IT)  
L7              QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR  
                LC(W)50)  
L8              QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT  
L9              QUE (INHAL? OR PULMON? OR NASAL? OR LUNG?  OR RESPIR?)  
L10             QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)  
L11             QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS 
OR  
                DIETARY OR DRINKING(W)WATER?)  
L12             QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR 
PERMISSIBLE)) 
 
L13             QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)  
L14             QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? 
OR  
                OVUM?)  
L15             QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)  
L16             QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR  
                TERATOGEN?)  
L17             QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR 
SPERMAS? OR  
                SPERMATOB? OR SPERMATOC? OR SPERMATOG?)  
L18             QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR 
SPERMATOX? OR  
                SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)  
L19             QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR 
DEVELOPMENTAL?)  
L20             QUE (ENDOCRIN? AND DISRUPT?)  
L21             QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR 
INFANT?)  
L22             QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)  
L23             QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)  
L24             QUE (CARCINOG? OR COCARCINOG? OR CANCER? OR PRECANCER? 
OR  
                NEOPLAS?)  
L25             QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR 
CARCINOM?)  
L26             QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR 
GENETIC(W)TOXIC?)  
L27             QUE (NEPHROTOX? OR HEPATOTOX?)  
L28             QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)  
L29             QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)  
L30             QUE L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR  
                L14 OR L15 OR L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR  
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29  
L31             QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR 
MURIDAE  
                OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR 
SWINE  
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
                OR PORCINE OR MONKEY? OR MACAQUE?)  
L32             QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR 
LAGOMORPHA  
                OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)  
L33             QUE L30 OR L31 OR L32  
L34             QUE (NONHUMAN MAMMALS)/ORGN  
L35             QUE L33 OR L34  
L36             QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? 
OR  
                PRIMATES OR PRIMATE?)  
L37             QUE L35 OR L36  
               --------- 
L38        1878 SEA L4 AND L37  
L39          94 SEA L38 AND MEDLINE/FS  
L40         178 SEA L38 AND BIOSIS/FS  
L41        1558 SEA L38 AND CAPLUS/FS  
L42          48 SEA L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS)  
L43        1737 DUP REM L39 L40 L42 L41 (141 DUPLICATES REMOVED) 
L*** DEL     94 S L38 AND MEDLINE/FS 
L*** DEL     94 S L38 AND MEDLINE/FS 
L44          94 SEA L43  
L*** DEL    178 S L38 AND BIOSIS/FS 
L*** DEL    178 S L38 AND BIOSIS/FS 
L45         149 SEA L43  
L*** DEL   1558 S L38 AND CAPLUS/FS 
L*** DEL   1558 S L38 AND CAPLUS/FS 
L46        1449 SEA L43  
L*** DEL     48 S L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS) 
L*** DEL     48 S L38 NOT (MEDLINE/FS OR BIOSIS/FS OR CAPLUS/FS) 
L47          45 SEA L43  
L48        1643 SEA (L44 OR L45 OR L46 OR L47) NOT MEDLINE/FS  
                D SCAN L48 
 
Table B-3.  Strategies to Augment the Literature Search 
 
Source Query and number screened when available 
TSCATSa  
04/2017 Compound searched: 108-90-7 
NTP  
04/2017 108-90-7 
Benzene chloride 
Chlorobenzene 
Monochlorobenzene 
Phenyl chloride 
NIH RePORTER 
11/2017 Text Search: "108-90-7" OR "Benzene chloride" OR "Chloorbenzeen" OR 
"Chlorbenzene" OR "Chlorbenzol" OR "Chlorobenzen" OR "Chlorobenzene" OR 
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Table B-3.  Strategies to Augment the Literature Search 
 
Source Query and number screened when available 
"mono-Chlorobenzene " OR "Chlorobenzenu" OR "Chlorobenzol" OR "Clorobenzene" 
OR "I P Carrier T 40" OR "Monochloorbenzeen" OR "Monochlorbenzene" OR 
"Monochlorbenzol" OR "Monochlorobenzene" OR "Monoclorobenzene" OR "Phenyl 
chloride" OR "Tetrosin SP" (Advanced),     Search in: Projects     AdminIC: All,   Fiscal 
Year: Active Projects 
Other Identified throughout the assessment process 
 
aSeveral versions of the TSCATS database were searched, as needed, by CASRN including TSCATS1 via Toxline 
(no date limit), TSCATS2 via https://yosemite.epa.gov/oppts/epatscat8.nsf/ReportSearch?OpenForm (date restricted 
by EPA receipt date), and TSCATS via CDAT (date restricted by ‘Mail Received Date Range’), as well as google for 
recent TSCA submissions. 
 
The 2017 results were:  
• Number of records identified from PubMed, TOXLINE, and TOXCENTER (after duplicate 
removal):  3,694 
• Number of records identified from other strategies:  69 
• Total number of records to undergo literature screening:  3,764 
 
B.1.2  Literature Screening 
 
A two-step process was used to screen the literature search to identify relevant studies on chlorobenzene:   
 
• Title and abstract screen 
• Full text screen 
 
Title and Abstract Screen.  Within the reference library, titles and abstracts were screened manually for 
relevance.  Studies that were considered relevant (see Table B-1 for inclusion criteria) were moved to the 
second step of the literature screening process.  Studies were excluded when the title and abstract clearly 
indicated that the study was not relevant to the toxicological profile.   
 
• Number of titles and abstracts screened:  3,764 
• Number of studies considered relevant and moved to the next step:  76 
 
Full Text Screen.  The second step in the literature screening process was a full text review of individual 
studies considered relevant in the title and abstract screen step.  Each study was reviewed to determine 
whether it was relevant for inclusion in the toxicological profile.   
 
• Number of studies undergoing full text review:  76 
• Number of studies cited in the health effect sections of the existing toxicological profile:  37 
• Total number of studies cited in health effects sections of the profile:  64 
 
A summary of the results of the literature search and screening is presented in Figure B-1. 
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Figure B-1.  April 2017 Literature Search Results and Screen for Chlorobenzene 
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APPENDIX C.  USER'S GUIDE 
 
Chapter 1.  Relevance to Public Health 
 
This chapter provides an overview of U.S. exposures, a summary of health effects based on evaluations of 
existing toxicologic, epidemiologic, and toxicokinetic information, and an overview of the minimal risk 
levels.  This is designed to present interpretive, weight-of-evidence discussions for human health 
endpoints by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
Minimal Risk Levels (MRLs) 
 
Where sufficient toxicologic information is available, ATSDR derives MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
 
MRLs should help physicians and public health officials determine the safety of a community living near 
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily 
dose in water.  MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  
Section 1.2, Summary of Health Effects, contains basic information known about the substance.  Other 
sections, such as Section 3.2 Children and Other Populations that are Unusually Susceptible and 
Section 3.4 Interactions with Other Substances, provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human variability to 
protect sensitive subpopulations (people who are most susceptible to the health effects caused by the 
substance) and for interspecies variability (extrapolation from animals to humans).  In deriving an MRL, 
these individual uncertainty factors are multiplied together.  The product is then divided into the 
inhalation concentration or oral dosage selected from the study.  Uncertainty factors used in developing a 
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substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables 
that are provided in Chapter 2.  Detailed discussions of the MRLs are presented in Appendix A. 
 
Chapter 2.  Health Effects 
 
Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species and MRLs to humans for noncancer 
endpoints.  The LSE tables and figures can be used for a quick review of the health effects and to locate 
data for a specific exposure scenario.  The LSE tables and figures should always be used in conjunction 
with the text.  All entries in these tables and figures represent studies that provide reliable, quantitative 
estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE tables and figures follow.  The numbers in the left column of the legends correspond to 
the numbers in the example table and figure. 
 
TABLE LEGEND 
See Sample LSE Table (page C-5) 
 
(1) Route of exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  
Typically, when sufficient data exist, three LSE tables and two LSE figures are presented in the 
document.  The three LSE tables present data on the three principal routes of exposure 
(i.e., inhalation, oral, and dermal).  LSE figures are limited to the inhalation and oral routes.  Not 
all substances will have data on each route of exposure and will not, therefore, have all five of the 
tables and figures.  Profiles with more than one chemical may have more LSE tables and figures. 
 
(2) Exposure period.  Three exposure periods—acute (<15 days), intermediate (15–364 days), and 
chronic (≥365 days)—are presented within each relevant route of exposure.  In this example, two 
oral studies of chronic-duration exposure are reported.  For quick reference to health effects 
occurring from a known length of exposure, locate the applicable exposure period within the LSE 
table and figure. 
 
(3) Figure key.  Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 51 identified NOAELs and less serious LOAELs (also see the three 
"51R" data points in sample LSE Figure 2-X). 
 
(4) Species (strain) No./group.  The test species (and strain), whether animal or human, are identified 
in this column.  The column also contains information on the number of subjects and sex per 
group.  Chapter 1, Relevance to Public Health, covers the relevance of animal data to human 
toxicity and Section 3.1, Toxicokinetics, contains any available information on comparative 
toxicokinetics.  Although NOAELs and LOAELs are species specific, the levels are extrapolated 
to equivalent human doses to derive an MRL. 
 
(5) Exposure parameters/doses.  The duration of the study and exposure regimens are provided in 
these columns.  This permits comparison of NOAELs and LOAELs from different studies.  In 
this case (key number 51), rats were orally exposed to “Chemical X” via feed for 2 years.  For a 
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more complete review of the dosing regimen, refer to the appropriate sections of the text or the 
original reference paper (i.e., Aida et al. 1992). 
 
(6) Parameters monitored.  This column lists the parameters used to assess health effects.  Parameters 
monitored could include serum (blood) chemistry (BC), behavioral (BH), biochemical changes 
(BI), body weight (BW), clinical signs (CS), developmental toxicity (DX), enzyme activity (EA), 
food intake (FI), fetal toxicity (FX), gross necropsy (GN), hematology (HE), histopathology 
(HP), lethality (LE), maternal toxicity (MX), organ function (OF), ophthalmology (OP), organ 
weight (OW), teratogenicity (TG), urinalysis (UR), and water intake (WI). 
 
(7) Endpoint.  This column lists the endpoint examined.  The major categories of health endpoints 
included in LSE tables and figures are death, body weight, respiratory, cardiovascular, 
gastrointestinal, hematological, musculoskeletal, hepatic, renal, dermal, ocular, endocrine, 
immunological, neurological, reproductive, developmental, other noncancer, and cancer.  "Other 
noncancer" refers to any effect (e.g., alterations in blood glucose levels) not covered in these 
systems.  In the example of key number 51, three endpoints (body weight, hematological, and 
hepatic) were investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  The body weight effect reported in key number 51 is a NOAEL at 
25.5 mg/kg/day.  NOAELs are not reported for cancer and death; with the exception of these two 
endpoints, this field is left blank if no NOAEL was identified in the study. 
 
(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific endpoint used to 
quantify the adverse effect accompanies the LOAEL.  Key number 51 reports a less serious 
LOAEL of 6.1 mg/kg/day for the hepatic system, which was used to derive a chronic exposure, 
oral MRL of 0.008 mg/kg/day (see footnote "c").  MRLs are not derived from serious LOAELs.  
A cancer effect level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects.  The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases.  If no LOAEL/CEL values were identified in the 
study, this field is left blank. 
 
(10) Reference.  The complete reference citation is provided in Chapter 8 of the profile. 
 
(11) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  For example, footnote "c" indicates that the LOAEL of 6.1 mg/kg/day in key 
number 51 was used to derive an oral MRL of 0.008 mg/kg/day. 
 
FIGURE LEGEND 
See Sample LSE Figure (page C-6) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the chronic exposure period are illustrated. 
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(14) Endpoint.  These are the categories of health effects for which reliable quantitative data exist.  
The same health effect endpoints appear in the LSE table. 
 
(15) Levels of exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) LOAEL.  In this example, the half-shaded circle that is designated 51R identifies a LOAEL 
critical endpoint in the rat upon which a chronic oral exposure MRL is based.  The key number 
51 corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 6.1 mg/kg/day (see entry 51 in the sample LSE table) to 
the MRL of 0.008 mg/kg/day (see footnote "c" in the sample LSE table). 
 
(17) CEL.  Key number 59R is one of studies for which CELs were derived.  The diamond symbol 
refers to a CEL for the test species (rat).  The number 59 corresponds to the entry in the LSE 
table. 
 
(18) Key to LSE figure.  The key provides the abbreviations and symbols used in the figure. 
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APPENDIX D.  QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances may find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Relevance to Public Health: The Relevance to Public Health Section provides an overview 
of exposure and health effects and evaluates, interprets, and assesses the significance of toxicity 
data to human health.  A table listing minimal risk levels (MRLs) is also included in this chapter. 
 
Chapter 2:  Health Effects: Specific health effects identified in both human and animal studies are 
reported by type of health effect (e.g., death, hepatic, renal, immune, reproductive), route of 
exposure (e.g., inhalation, oral, dermal), and length of exposure (e.g., acute, intermediate, and 
chronic).   
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.   
 
Pediatrics:    
 Section 3.2 Children and Other Populations that are Unusually Susceptible 
 Section 3.3  Biomarkers of Exposure and Effect  
 
 
ATSDR Information Center  
 
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   
 Internet:  http://www.atsdr.cdc.gov 
 
The following additional materials are available online: 
 
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary 
health care providers’ knowledge of a hazardous substance in the environment and to aid in the 
evaluation of potentially exposed patients (see https://www.atsdr.cdc.gov/csem/csem.html).   
 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides 
to assist first responders and hospital emergency department personnel in planning for incidents 
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute 
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials. 
 
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp). 
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Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:  
https://www.cdc.gov/nceh/. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page: 
https://www.niehs.nih.gov/. 
 
 
Clinical Resources (Publicly Available Information) 
 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:  
http://www.acoem.org/. 
 
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with 
recognized expertise in medical toxicology.  Contact:  ACMT, 10645 North Tatum Boulevard, 
Suite 200-111, Phoenix AZ 85028 • Phone:  844-226-8333 • FAX:  844-226-8333 • Web Page:  
http://www.acmt.net. 
 
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the 
public about the impact of environmental factors on the health of children and reproductive-aged 
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html. 
 
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA 
22314 • Phone:  701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:  
http://www.aapcc.org/. 
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APPENDIX E.  GLOSSARY 
 
 
Absorption—The process by which a substance crosses biological membranes and enters systemic 
circulation.  Absorption can also refer to the taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of ≤14 days, as specified in the Toxicological 
Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD) or Benchmark Concentration (BMC)—is the dose/concentration 
corresponding to a specific response level estimate using a statistical dose-response model applied to 
either experimental toxicology or epidemiology data.  For example, a BMD10 would be the dose 
corresponding to a 10% benchmark response (BMR).  The BMD is determined by modeling the dose-
response curve in the region of the dose-response relationship where biologically observable data are 
feasible.  The BMDL or BMCL is the 95% lower confidence limit on the BMD or BMC.   
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Indicators signaling events in biologic systems or samples, typically classified as markers 
of exposure, effect, and susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of a chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population and 
its appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome. 
 
Case Report—A report that describes a single individual with a particular disease or exposure.  These 
reports may suggest some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Reports that describe the experience of a small number of individuals with the same 
disease or exposure.  These reports may suggest potential topics for scientific research, but are not actual 
research studies. 
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Ceiling Value—A concentration that must not be exceeded.  
 
Chronic Exposure—Exposure to a chemical for ≥365 days, as specified in the Toxicological Profiles. 
 
Clastogen—A substance that causes breaks in chromosomes resulting in addition, deletion, or 
rearrangement of parts of the chromosome. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome, and who are disease-free at start of follow-up.  Often, at 
least one exposed group is compared to one unexposed group, while in other cohorts, exposure is a 
continuous variable and analyses are directed towards analyzing an exposure-response coefficient. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at a specific point in time. 
 
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of 
human health risk assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the response or amount of the response. 
  
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
effect occurs.  Effects include malformations and variations, altered growth, and in utero death. 
 
Epidemiology—The investigation of factors that determine the frequency and distribution of disease or 
other health-related conditions within a defined human population during a specified period.  
 
Excretion—The process by which metabolic waste products are removed from the body.  
  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one-half of a quantity of a chemical from 
the body or environmental media. 
 
Health Advisory—An estimate of acceptable drinking water levels for a chemical substance derived by 
EPA and based on health effects information.  A health advisory is not a legally enforceable federal 
standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or 
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health. 
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Immunotoxicity—Adverse effect on the functioning of the immune system that may result from 
exposure to chemical substances.   
 
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.  
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
  
Metabolism—Process in which chemical substances are biotransformed in the body that could result in 
less toxic and/or readily excreted compounds or produce a biologically active intermediate. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
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Morbidity—The state of being diseased; the morbidity rate is the incidence or prevalence of a disease in 
a specific population. 
 
Mortality—Death; the mortality rate is a measure of the number of deaths in a population during a 
specified interval of time. 
 
Mutagen—A substance that causes mutations, which are changes in the DNA sequence of a cell’s DNA.  
Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Although effects may be produced at this dose, they 
are not considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor).  An odds ratio that is greater than 1 is considered to indicate greater risk of 
disease in the exposed group compared to the unexposed group. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air 
averaged over any 8-hour work shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals). 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic 
endpoints.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.  
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Physiologically Based Pharmacokinetic (PBPK) Model—A type of physiologically based dose-
response model that is comprised of a series of compartments representing organs or tissue groups with 
realistic weights and blood flows.  These models require a variety of physiological information, including 
tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly 
membrane permeabilities.  The models also utilize biochemical information, such as blood:air partition 
coefficients, and metabolic parameters.  PBPK models are also called biologically based tissue dosimetry 
models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
 
Prospective Study—A type of cohort study in which a group is followed over time and the pertinent 
observations are made on events occurring after the start of the study.   
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation RfC is expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily oral exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious noncancer health effects during a lifetime.  The oral RfD is expressed in units of mg/kg/day.   
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  RQs are 
(1) ≥1 pound or (2) for selected substances, an amount established by regulation either under CERCLA or 
under Section 311 of the Clean Water Act.  Quantities are measured over a 24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or 
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance. 
 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of 
disease or other health-related event or condition. 
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Risk Ratio/Relative Risk—The ratio of the risk among persons with specific risk factors compared to the 
risk among persons without risk factors.  A risk ratio that is greater than 1 indicates greater risk of disease 
in the exposed group compared to the unexposed group. 
 
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be 
exceeded at any time during a workday.   
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly 
exposed, day after day, for a working lifetime without adverse effect.  The TLV may be expressed as a 
Time-Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling 
limit (TLV-C). 
 
Time-Weighted Average (TWA)—An average exposure within a given time period.   
 
Toxicokinetic—The absorption, distribution, metabolism, and elimination of toxic compounds in the 
living organism. 
 
Toxics Release Inventory (TRI)—The TRI is an EPA program that tracks toxic chemical releases and 
pollution prevention activities reported by industrial and federal facilities.   
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL), 
Reference Dose (RfD), or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis (3 being the approximate logarithmic 
average of 10 and 1). 
 
Xenobiotic—Any substance that is foreign to the biological system. 
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APPENDIX F.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
AAPCC 
ACGIH 
ACOEM 
ACMT 
ADI 
ADME 
AEGL 
AIC 
AIHA 
ALT 
AOEC 
AP 
AST 
atm 
ATSDR 
AWQC 
BCF 
BMD/C 
BMDX 
BMDLX 
BMDS 
BMR 
BUN 
C 
CAA 
CAS 
CDC 
CEL 
CERCLA 
CFR 
Ci 
CI 
cm 
CPSC 
CWA 
DNA 
DOD 
DOE 
DWEL 
EAFUS 
ECG/EKG 
EEG 
EPA 
ERPG 
F 
F1 
FDA 
FIFRA 
American Association of Poison Control Centers 
American Conference of Governmental Industrial Hygienists 
American College of Occupational and Environmental Medicine 
American College of Medical Toxicology 
acceptable daily intake 
absorption, distribution, metabolism, and excretion 
Acute Exposure Guideline Level 
Akaike’s information criterion  
American Industrial Hygiene Association  
alanine aminotransferase 
Association of Occupational and Environmental Clinics 
alkaline phosphatase 
aspartate aminotransferase 
atmosphere 
Agency for Toxic Substances and Disease Registry 
Ambient Water Quality Criteria 
bioconcentration factor 
benchmark dose or benchmark concentration 
dose that produces a X% change in response rate of an adverse effect 
95% lower confidence limit on the BMDX 
Benchmark Dose Software   
benchmark response 
blood urea nitrogen  
centigrade 
Clean Air Act 
Chemical Abstract Services 
Centers for Disease Control and Prevention 
cancer effect level 
Comprehensive Environmental Response, Compensation, and Liability Act 
Code of Federal Regulations 
curie 
confidence interval 
centimeter 
Consumer Products Safety Commission 
Clean Water Act 
deoxyribonucleic acid 
Department of Defense 
Department of Energy 
drinking water exposure level 
Everything Added to Food in the United States  
electrocardiogram 
electroencephalogram 
Environmental Protection Agency 
emergency response planning guidelines  
Fahrenheit 
first-filial generation 
Food and Drug Administration 
Federal Insecticide, Fungicide, and Rodenticide Act 
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FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GGT γ-glutamyl transferase  
GRAS  generally recognized as safe  
HEC  human equivalent concentration  
HED  human equivalent dose  
HHS  Department of Health and Human Services  
HPLC high-performance liquid chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
IRIS Integrated Risk Information System   
Kd adsorption ratio 
kg kilogram 
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Level of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
mmol millimole 
MRL Minimal Risk Level 
MS mass spectrometry 
MSHA Mine Safety and Health Administration 
Mt metric ton 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NCEH National Center for Environmental Health 
ND not detected 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
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NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NTP National Toxicology Program 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
PAC  Protective Action Criteria  
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PEHSU Pediatric Environmental Health Specialty Unit 
PEL permissible exposure limit 
PEL-C permissible exposure limit-ceiling value 
pg picogram 
PND postnatal day 
POD point of departure 
ppb parts per billion 
ppbv parts per billion by volume 
ppm parts per million 
ppt parts per trillion 
REL recommended exposure level/limit 
REL-C recommended exposure level-ceiling value 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SD standard deviation 
SE standard error 
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST) 
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT) 
SIC standard industrial classification 
SMR standardized mortality ratio 
sRBC sheep red blood cell 
STEL short term exposure limit 
TLV threshold limit value 
TLV-C threshold limit value-ceiling value 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
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USNRC U.S. Nuclear Regulatory Commission 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
 
> greater than 
≥ greater than or equal to 
= equal to 
< less than 
≤ less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
μm micrometer 
μg microgram 
q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
 
